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ABSTRACT 
NOTCH1 MODIFICATION AND SIGNALING IN T HELPER CELL 
DIFFERENTIATION 
MAY 2017 
KARTHIK CHANDIRAN, B.TECH., ANNA UNIVERSITY – CHENNAI, INDIA 
Ph.D., UNIVERSITY OF MASSACHUSETTS – AMHERST 
Directed by: Dr. Lisa M. Minter 
Notch signaling modulates the developmental program of multiple cell types. The 
cleaved intracellular region of the receptor possess the functional domain which 
influences T cell activation, proliferation and differentiation. However, in naïve CD4 T 
cells the mechanistic details underlying cleavage of Notch1 is not clearly understood. 
Notch functions by acting as a signaling hub and interacting with its canonical (CSL) and 
non-canonical (NFB, mTOR, Akt) binding partners to cross-talk with other signaling 
pathways. Notch signaling drives the differentiation program of multiple T helper cell 
subsets (Th1, Th2, Th17, Th9, iTreg and TFH). Recent discoveries also demonstrated a 
role for microRNAs in T helper cell differentiation, particularly in Th1 cells. The miR-29 
family of microRNAs limit Th1 differentiation by directly targeting the signature 
molecules of Th1 cells, ifng and tbx21. The post translational modifications of Notch1 
during activation and differentiation of CD4 T cells are described here. We specifically 
demonstrate that Notch1 is constitutively cleaved in naïve cells and it is hyper-
phosphorylated. Phosphorylation status of Notch1 changes upon TCR mediated 
activation, probably through dephosphorylation, resulting in different forms of 
vii 
 
phosphorylated Notch1. In Chapter 3, we study Notch1-mediated regulation of miR-29. 
We show that Notch1 suppresses miR-29 through CSL-dependent, canonical Notch 
signaling. Thus, our data indicate a novel mechanism for regulating miR-29 transcription 
in addition to STAT1 and NFB. We demonstrated that Notch1 and IFN act in an 
opposing manner to regulate the expression of miR-29, therefore modulating Th1 
response. 
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CHAPTER 1 
 
INTRODUCTION 
1.1. T Cell Activation and Differentiation 
1.1.1. T cell Activation 
Naïve CD4+ (helper-Th) or CD8
+ (cytotoxic-Tc) T cells possess unique T cell receptor 
(TCR) on their cell surface. Foreign antigens are presented to T cells by major 
histocompatibility complex (MHC) present on the antigen presenting cells (APCs). The 
engagement of TCR and MHC triggers the initiation of the adaptive immune response. In 
addition, ligation of other cell surface receptors provide co-stimulation to CD4+ T cells. 
CD28 which binds to its ligands CD80/CD86 on APCs, is the major co-stimulatory 
molecule that delivers a robust response. TCR and CD28 engagement activate a 
downstream signaling cascade in helper T cells that results in their proliferation and 
differentiation into specific effector and memory cells 1.  
1.1.2. CD4 T cell differentiation 
The differentiation of CD4+ T cells to different subsets depends on the cytokine milieu of 
the environment (Figure1.1). The early source of key cytokines that initiates their 
differentiation come from the innate immune system which is then augmented by the 
cytokines secreted by the CD4+ T cells. During this process the helper T cells can 
differentiate into following subsets: 
Th1: IL-12 and IFN are the key cytokines responsible for driving Th1 differentiation and 
the T-box transcription factor (T-bet) is the lineage-defining transcription regulator which 
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further enhances the production of IFN by Th1 cells 1-4. In addition, T-bet also inhibits 
the differentiation towards other subsets by inhibiting the expression of master regulators 
directly or sequestering away the key transcription factors involved 2-4. In Th1 cells, 
signaling mediated by signal transduce and activator of transcription (STAT) proteins, 
STAT1 and STAT4, play a complementary role in inducing the expression of T-bet and 
IFN. During Th1 differentiation, IL-12-induced STAT4 leads to the production of IFN 
which in turn induces STAT1 expression to trigger the transcription of T-bet. This forms 
a positive feedback loop to have sustained Th1 response 
1, 2, 5, 6.  
Th2: IL-4 and IL-2 are the crucial cytokines responsible for driving Th2 differentiation 
and GATA3 is the master transcriptional regulator. Similar to Th1 differentiation, Th2 
differentiation also happens through a STAT dependent pathway, where IL-4 induces the 
expression of GATA3 through STAT61, 7-9. Also, GATA3 prevents Th1 differentiation by 
inhibiting the expression of STAT4 1, 10. In addition to IL-4 signaling, IL-2-induced 
STAT5 also has been shown to play an important role in the differentiation process 
independent of GATA3 1, 11-13. 
Th17: IL-6, IL-21, IL-23 and TGFβ are the crucial cytokines that induce Th17 
differentiation and the retinoic acid receptor-related orphan receptor t (RORt) is the 
master transcriptional regulator 1, 14-18. The signature cytokines of Th17 cells, IL-17A and 
IL-17F are transcribed by RORt. In the case of Th17, the cytokines IL-6, IL-21 and IL-
23 induce the activation of STAT3, which is required for RORt expression18.  
Regulatory T cells: The regulatory T cells are the subset of helper T cells which modulate 
the immune system by suppressing the response generated by T cells. Two different 
subsets of regulatory T cells (Treg) exist: (i) naturally occurring Treg (nTreg) which are 
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developed in the thymus as a unique subset and express the Forkhead transcription factor, 
FoxP3 1, 19. (ii) induced Tregs (iTregs) arise from naïve CD4+ T cells in peripheral 
lymphoid organs and can be generated in vitro 20. TGFβ is the critical cytokine required 
for the differentiation of iTregs and FoxP3 is the lineage-defining transcription factor 1, 21-
23. Upon activation of CD4+ T cells, TGFβ induces the expression of FoxP3 1, 19. IL-2 
dependent STAT5 signaling is required for the expression of FoxP3 and thereby the 
development of iTregs 1, 24-27. 
Follicular helper T cells: These cells are present in the follicular areas of lymphoid 
organs, where they are involved in B cell mediated immune response. While IL-6 and  
IL-21 are the critical cytokines required, STAT3 and Bcl6 are the important transcription 
factors that are required for Tfh differentiation 
1, 28, 29. In contrast to Th17 and iTreg 
differentiation, TGFβ and RORt are not involved in the development of Tfh cells. Also, 
in the absence of TGFβ, IL-21 alone can induce Tfh differentiation30.  
In addition, there are also other less well characterized subsets of CD4+ T helper cells 
such as Th9 and Th22 cells. Recent recent reports have indicated that Th17 and iTreg 
subsets can be plastic and switch to a different subset depending on the presence of 
appropriate cytokines 1, 31-34. 
1.2. Notch Signaling 
1.2.1. Notch receptors and ligands 
Notch is an evolutionarily well-conserved transmembrane receptor that determines cell 
fate through interaction with its ligands. It was first identified in Drosophila 
melanogaster, where partial loss of Notch led to notches in the wing35, 36. Moreover, 
certain loss-of-function mutants of Notch induced differences in cell fate and 
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phenotype35, 37. This dramatic phenotype observed in flies opened a plethora of research 
about Notch signaling in diverse developmental and physiological processes.  In 
mammals, there are four Notch receptors (Notch1-4) and CD4+ T cells possess only 
Notch1-3 with Notch4 being absent (Figure 1.2)38. These Notch proteins are type I 
transmembrane heterodimeric receptors that are activated by ligands. Similar to the 
receptors, Canonical Notch ligands are also type I transmembrane proteins that belong to 
two different families Delta-like (DLL1, DLL3, DLL4) and Jagged (Jag1, Jag2)38 (Figure 
1.3). 
1.2.2. Structure of Notch and its ligands 
The extracellular portion of Notch is comprised predominantly of tandem epidermal 
growth factor (EGF) like repeats followed by three cysteine rich Lin-12/ Notch repeats 
(LNR)39. The heterodimerization (HD) domain is sandwiched between the LNR and 
transmembrane domains39. Together, the LNR and HD domains form the negative 
regulatory region (NRR) of the Notch receptor. The NRR protects cleavage of Notch by 
metalloproteases in the absence of ligands39, 40. Notch receptors undergo a first 
proteolytic cleavage (S1) at the HD domain, by a furin-like protease in trans-Golgi 
network, to form the mature receptor35, 41. Cleaved Notch receptors are presented at the 
cell surface as a heterodimer through non-covalent interactions between the N-terminal 
and C-terminal regions of HD domain35, 42, 43. The intracellular domain is the important 
region of the Notch receptor which possesses multiple functional domains and relays the 
signal downstream. This includes the RAM (recombination binding protein –J associated 
molecule) domain, Ankyrin domain (seven ANK repeats), the variable transactivation 
domain at the N-terminus and a PEST domain at the C-terminus39, 44. It also contains a 
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bipartite nuclear localization signal (NLS) which allows the translocation of the 
intracellular domain to the nucleus (Figure 1.2). 
Canonical Notch ligands are characterized by the presence of highly conserved DSL 
(Delta, Serrate and Lag2) domains in their N-terminus. Similar to Notch receptor, its 
ligands also possess several EGF repeats in their extracellular domain. In addition to DSL 
domains, certain canonical Notch ligands (Jag1, Jag2 and DLL1) possess a novel 
conserved motif between two EGF repeats at the N-terminus called DOS (Delta and 
OSM-11) domain41, 45 (Figure 1.3). 
1.2.3. Canonical Notch Signaling 
Notch receptors, upon encountering ligands, reveal an otherwise buried S2 cleavage site 
in the HD domain46. This triggers a series of proteolytic cleavage events, first by ADAM 
(a disintegrin and metalloprotease) proteases, which renders the receptor susceptible to 
subsequent intramembrane/intracellular cleavage processes. The S2 cleavage can be 
mediated by two ADAMs, ADAM10 (Kuzbanian/Kuz) and tumor necrosis factor- 
converting enzyme (TACE/ADAM17)47. The S3 cleavage happens in the intracellular 
domain of Notch (NICD) by -secretase39, 48-50, a multiprotein complex that consists of 
presenilin1 (PEN1), nicastrin, PEN2 and APH1, resulting in the release of NICD into the 
cytosol51-53. The NLS allows it to translocate to the nucleus (Gordon Jarriault) where it 
can activate the transcription of its target genes such as Hairy/enhancer of split (Hes)41, 54. 
The nuclear NICD interacts with CSL (CBF1, Suppressor of Hairless, Lag-1)/RBPJ 
(Recombination Signal Binding protein for immunoglobulin kappa J), which is bound to 
the promoters and enhancers of target genes together with co-repressor molecules like 
SMRT (Silencing Mediator of Retinoid and Thyroid Hormone receptors), SHARP 
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(SMRT/HDAC1 associated repressor protein), SKIP (Ski-interacting protein) and CIR 
(CBF1-interacting corepressor)38, 55-58. NICD interaction displaces the co-repressors and 
recruits Mastermind-like proteins which act as a scaffold for the formation of larger 
multimeric protein complexes59-61. This event leads to the recruitment of transcriptional 
activators like p300 and CBP (CREB binding protein)39, 62, 63. The transcription of target 
genes, through the formation of protein-DNA complex in a CSL-dependent manner is 
termed Canonical Notch signaling (Figure 1.5). 
1.2.4. Non-Canonical Notch signaling 
There are several reports indicating that Notch can also function in a CSL-independent, 
DSL ligand-independent (through non-canonical Notch ligands) or completely through a 
ligand-independent pathway, which forms the non-canonical Notch signaling/pathway. 
Early evidence for such a mechanism was observed in Drosophila, where CSL-
independent activity of Notch was observed during muscle development 64-67. In CSL-
independent Notch signaling, NICD interacts with other molecules resulting in cross-talk 
with different signaling pathways which includes Wnt, NF-B, JAK/STAT and mTOR68, 
69. In particular, the interplay of Notch signaling with the Wnt pathway70, 71 and NF-B 
signaling have been studied extensively60, 72-75 (Figure 1.6).  
The first reported non-canonical Notch ligand is Delta-like 1 (Dlk-1), which is 
structurally similar to other Delta-like proteins but lacks the DSL domain45, 76-79. Instead, 
Dlk-1 has a DOS domain like Jag1, and has been reported to antagonize Jag1-mediated 
Notch signaling by competing with it45, 80. Other DSL domain-lacking Notch ligands are 
Delta/Notch-like EGF related receptor (DNER) and a putative DSL ligand-like protein 
called Jagged and Delta (Jedi)45, 81, 82. In addition, there are also certain GPI anchored 
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ligands (Contactin1/6) 77, 83and a variety of secreted proteins have been identified in flies 
(Scabrous, Wingless)45, 84-86, worms (OSM11, DOS1),45, 87 and vertebrates (CCN3, 
MAGP2) that can activate the Notch pathway (Figure 1.4) 45, 88-90. 
The other pathway for non-canonical Notch signaling is through vesicular transport 
which is independent of Notch ligands64, 91. Here the endocytosed Notch receptors 
activate or suppress signaling depending on the location64, 92, 93. 
A recent report identified a novel non-canonical signaling pathway in neurons, which is 
ligand dependent but -secretase independent. Here, neuron specific deletion of Notch 
results in decreased expression of synaptic vesicle proteins however treatment with -
secretase inhibitors did not have any effect suggesting the S3 cleavage is dispensable94 
(Figure 1.7). 
1.2.5. Post-translational modifications of Notch 
Notch receptors are susceptible to multiple post-translational modifications (PTM) which 
include glycosylation, ubiquitination, phosphorylation, and acetylation (Figure 1.8)95. 
Notch signaling is regulated at various stages by PTM of Notch intracellular domain to 
activate signaling events through phosphorylation or switch off the signaling process by 
ubiquitin-mediated proteasomal degradation. The different PTMs of Notch receptors are 
as follow: 
Glycosylation: The extracellular domain of Notch has around 29-36 EGF-like repeats 
which are the sites for glycosylation. It is a key event in Notch activation and lack of 
glycosylation leads to dysfunctional Notch signaling. The first sugar moiety is added to 
the receptor by O-fucosyl transferase (O-fut) generating a functional Notch receptor38, 96-
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99. Fringe is a family (Lunatic Fringe, Manic Fringe, Radical Fringe) of glycosyl 
transferase that can glycosylate Notch and biases the receptor towards Delta-mediated 
activation and resistance to Jagged-induced signaling38, 100-102. In particular, lunatic fringe 
plays an important role in T cell development by inhibiting Jagged-mediated Notch 
signaling and facilitating DLL-mediated Notch signaling41, 103-105. 
Ubiquitination: Multiple E3 ubiquitin ligases have been identified to ubiquitinate Notch 
receptors. In the canonical Notch pathway, the disassembly of the Notch-CSL complex 
requires proteasomal degradation of NICD which is facilitated by the E3 ligase FBW7 
(mammals)/ SEL10 (worms)38, 55. The E3 ligases, Itch (mammals)/ Suppressor of Deltex 
(fly) and c-Cbl are required for degradation of NICD and downregulate its activation. 
Moreover, ubiquitination is highly involved in ligand-independent signaling and 
determines the activation of NICD38, 106-110.  The E3 ligase, Deltex, has been found to 
promote the activation of Notch signaling by stabilizing the receptor in the endocytic 
vesicles. In studies overexpressing Deltex, there was increased accumulation of 
monoubiquitinated Notch and ligand independent activation95, 111, 112. 
Phosphorylation: NICD has multiple sites for phosphorylation especially on its C-
terminal PEST domain, and undergoes hyper-phosphorylation upon activation113. 
Proteasomal degradation of NICD by FBW7 is triggered by phosphorylation of its PEST 
domain by cyclin dependent kinase 8 (CDK8)55, 114, 115. Mutation in the PEST domain 
leads to accumulation of NICD and in some cases promotes tumor development40, 114. 
Similarly, Glycogen synthase kinase-3β (GSK-3β) also regulates NICD, however the 
function of GSK-3β mediated phosphorylation is controversial116-119. Recent evidence 
indicates that the phosphorylation status of Notch plays a crucial role in localization of 
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Notch120-123. Studies performed in mammalian cell lines have identified that kinases Akt 
and Nemo-like kinase (NLK) can target mammalian Notch receptors Notch 1, 3 and 4 
and negatively regulate their transcriptional activity120, 121, 123. Interestingly, NICD has 
been found to undergo differential phosphorylation in the presence of different cytokines. 
Milner and colleagues discovered that different residues of the Notch cytokine response 
(NCR) domain in NICD are phosphorylated in the presence of GM-CSF and G-CSF, to 
determine the fate of myeloid progenitor cells124, 125. 
Acetylation: Similar to phosphorylation, acetylation also offers a reversible mechanism 
for activation of Notch signaling. It has been identified that multiple residues present in 
RAM and Ankyrin domain are acetylated which inhibits proteasomal degradation of 
NICD. The effect of acetylation is reversed by SIRT1 deacetylase and leads to decreased 
levels of NICD95, 126. The histone acetyl transferase Tip60 has been shown to acetylate 
several lysine residues in NICD95, 127. Tip60-mediated acetylation of Notch1 inhibits its 
interaction with the canonical binding partner RBPJ and inhibits the transcription of 
Notch target genes95, 127. 
1.3. Role of Notch signaling in CD4 T cells 
1.3.1. Notch signaling in CD4 T cell development and activation 
Notch receptors play a crucial role in T cell development, where the loss-of-function of 
Notch1 led to a remarkable decrease in the size of the thymus and increased the number 
of B cells128-130. Conversely, over-expression of Notch1 intracellular domain (N1-ICD) in 
hematopoietic stem cells resulted in increased numbers of T cells while inhibiting the 
development of B cells in the bone marrow 129, 131. This suggests that Notch1 activation is 
extremely important for the cell fate determination of T and B cells.  
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N1-ICD has been shown to co-localize with TCR signaling components like p56 lck132 
and co-receptor CD4 after activation133. In Jurkat T cells, N1-ICD has been shown to 
regulate the expression of antiapoptotic molecules through PI3K and p56lck 132. In 
addition to interacting with key signaling molecules of TCR activation, Notch regulates 
the proliferation of CD4+ T cells and induces the expression of IL-2 and IFN74. 
Interestingly, a recent report by Fowlkes and colleagues identify the DLL4-Notch axis to 
be involved in a co-stimulatory role in T cell activation process134. DLL4-mediated Notch 
activation resulted in improved primary response at lower of doses of antigen and this 
process depends on PI3K mediated signaling downstream of TCR and CD28134. The co-
stimulatory function of canonical Notch signaling also ensured the activated T cells 
survive longer by creating an anti-apoptotic gene profile without affecting the 
proliferation135.  
In spite of longstanding research regarding Notch signaling, the activation of Notch1 in T 
cells is not completely understood. Although TCR-mediated activation has been shown to 
be sufficient to cause -secretase-dependent cleavage of Notch174, we do not know what 
triggers the S2 cleavage in this process. Current evidence point towards ligands present 
on both APCs and activated T cells, as well as endocytosis-mediated ligand independent 
activation134.  
1.3.2. Notch and T helper cell differentiation 
Over the last decade, multiple groups have identified different and contradictory roles for 
Notch in CD4+ T helper cell differentiation136. One potential reason for these opposing 
effects of Notch could be differences in the experimental models used for the deletion or 
inhibition of Notch activity. As Notch has been well-demonstrated to have a variety of 
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activation mechanisms, the differences in experimental models could have affected Notch 
at different stages causing a specific outcome. In early 2000s, Yasumoto and colleagues, 
as well as Flavell and colleagues, showed that different Notch ligands can determine the 
phenotype of T helper cells 137-139. While the data from our group showed that -secretase 
-mediated Notch1 signaling is required for Th1 differentiation and not Th2 differentiation, 
Pear and his colleagues reported that RBPj-dependent Notch signaling is required for Th2 
differentiation and not Th1
140, 141. Also, in a recent report from Pear’s group they showed 
that Notch can directly regulate IFN through an RBPj-dependent and T-bet independent 
mechanism142. Interestingly, using conditional Notch1-Notch2 double knock out animals, 
both the receptors have been shown to play a redundant role in IFN expression during 
Leishmania major infection143. In addition to Th1 and Th2, reports from other groups have 
implicated Notch signaling in differentiation of Th17 and Tregs as well 
144-147. Especially 
in the case of regulatory T cells, canonical Notch signaling plays an important role by 
negatively regulating the key components of Tregs and programming them towards a Th1 
phenotype148. Furthermore, Notch signaling has been shown to be required for T 
follicular helper cells as well. The abrogation of Notch signaling in Notch1-Notch2 
double knock out animals led to impaired differentiation of TFH and negatively affected 
germinal center (GC) B cell development149. 
While so far, the reports have indicated that Notch signaling can only drive T helper cells 
towards any one particular subset, a recent study by Pear and colleagues showed Notch 
signaling can concurrently regulate multiple subsets by directly facilitating the 
transcription of signature molecules142. Furthermore, contradicting all the other previous 
reports, Kopan’s group, using a Notch ligand expressing CHO-APC system showed that 
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Notch signaling only augments the cytokine production and is not involved in T helper 
cell differentiation150.  
The completely contrasting roles of Notch1 in CD4+ T cell differentiation, proposed by 
different groups further highlights that Notch signaling is highly context-dependent. 
Through differences in ligands, activation mechanisms, and binding partners it can have a 
variety of roles in different physiological systems. 
1.4. Non-coding RNAs 
In mammals, a large part of the genome remain untranslated and do not code for any 
proteins. However, these regions undergo transcription and the non-coding RNA 
molecules are grouped into two categories: small RNAs and long RNAs. The small RNA 
family comprises different subsets of RNAs which are further classified based on their 
function and length. This subset includes Micro RNAs (miRNA), small interfering RNA 
(siRNA), piwi-interacting RNA (piRNA), small nuclear and nucleolar RNA (snoRNA), 
promoter-associated small RNA, transcription initiation RNA, centromere repeat- 
associated small interacting RNA (crasiRNA), telomere specific small RNA (tel-sRNA) 
and pykons151, 152. These RNA molecules are generally termed small RNAs, the length of 
which varies from 18-300 nucleotides. The long non-coding RNAs (lncRNAs) are several 
hundred to several thousand nucleotides in length, and are identified by their genomic 
foci. These lncRNAs can exist in the sense strand or anti-sense strand, can be intronic or 
can even be intergenic152. 
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1.4.1. MicroRNAs 
miRNAs are small endogenous single stranded RNAs of about 22 nucleotides in 
length153. They are transcribed by RNA polymerase II, initially as a longer transcript (70 
nucleotides) called primary miRNA (pri-miRNA)154. Subsequently, pri-miRNA 
undergoes processing by an endonuclease called Drosha, producing precursor-miRNA 
(pre-miRNA). The pre-miRNA is then transported to the cytosol through Exportin V and 
processed by another endonuclease, Dicer, transforming pre-miRNA to mature miRNA. 
The region comprising the nucleotides at postion 2-8 from the 5’ end is called the seed 
sequence which determines the target mRNAs155. miRNAs binds to the complementary 
site in the 3’ untranslated regions (UTRs) of target mRNAs156 and then load the target 
mRNA onto Argonaute-protein containing RNA-induced silencing complex (RISC). 
miRNAs provide an additional layer of gene regulation by causing either translational 
inhibition or degradation of target mRNA, depending on the complementarity between 
the miRNA and the 3’ UTR of the mRNA.  
Due to the short nature of miRNAs, they tend to have multiple targets and also multiple 
miRNAs can target the same individual transcript at the same time. Usually, the effect of 
miRNAs are not very dramatic under physiological conditions and are employed to set a 
threshold limit on their targets. Since miRNA-regulated genes are always a part of a 
signaling pathway, a small change in the expression of certain related genes can have 
biologically relevant outcomes due to feedback mechanisms.  
1.4.2. Role of miRNAs in T cells 
miRNAs play an important role in regulation of various aspects of the immune system 
including development, activation, proliferation and differentiation. For instance, miR-
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181 is expressed at higher levels in thymocytes during development and inhibit the 
expression of TCR, CD69 and Bcl-2 156, 157. Moreover, studies performed using deletion 
of key miRNA processing molecules led to poor survival of T cells after activation155, 158-
162. miR-1792 is a family of miRNAs that plays an important role in T cell survival and 
proliferation. In CD4+ T cells, the transcription factor c-Myc induces the expression of 
the miR-1792 gene cluster, which in turn targets the gene downstream of c-Myc, E2F1. 
c-Myc-mediated regulation of cell proliferation through E2F1 and miR-1792 provides a 
classic example of miRNAs, where c-Myc triggers the cell proliferation through E2F1 
and also activates miRNAs for moderation to prevent unrestrained proliferation156, 163. 
Similar to T cell development, studies have been done using miRNA deficient 
experimental models to identify its role in T helper cell differentiation. These studies led 
to the conclusion that miRNA-deficient CD4+ T helper cells caused aberrant expression 
of signature cytokines and a biased T helper cell differentiation155, 158, 161, 164. By using 
deletion and over-expression strategies, several miRNAs including miR-29, miR-21 and 
let-7 were identified to regulate Th1, Th2, and Th17 differentiation respectively160, 162, 165-
167. Furthermore, miR-125p alone can prevent differentiation to effector cells by 
downregulating the expression of IFN, IL-2Rβ, IL-10R and PRDM1, thereby 
enforcing a naïve state167. However, more studies need to be done to clearly understand 
the mechanisms behind the expression of particular miRNAs at different stages of T cell 
development, proliferation and differentiation. 
1.5.Rationale, Specific Aims and Significance 
As summarized in the previous sections of this chapter, the function of Notch signaling in 
T cell differentiation has been extensively studied. Multiple studies have described that 
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activation of CD4 T cells leads to increased expression of cleaved active Notch174. 
However, the precise mechanism behind activation of Notch signaling is not known. Due 
to the absence of Notch ligands on naïve T cells it has been suggested that it could be a 
ligand-independent process but the results remain inconclusive. It is imperative to 
identify the activation mechanism as it would provide an additional avenue through 
which to the target Notch pathway, which has broader impact in several autoimmune 
diseases. Thus, the first aim of this study is to address the mechanism behind cleavage of 
Notch1 in CD4 T cells. 
N1-ICD generated downstream of TCR activation is involved in differentiation of 
multiple T helper cell subsets. In particular, Notch regulates Th1 differentiation by 
directly targeting the lineage-defining transcription factor, T-bet, and the signature 
cytokine IFN. Similarly, different groups reported that Notch promotes differentiation of 
other T helper cell subsets by inducing the expression of multiple protein through 
different means136. Recent studies discovered that miRNAs are crucial for T cell 
differentiation into different subsets and lack of miRNAs biased the differentiation 
towards Th1. Furthermore, miR-29 was identified as the family of miRNA that regulates 
Th1 differentiation by directly targeting its signature molecules tbx21, ifng and eomes
160, 
162, 168. NFB, a non-canonical binding partner of Notch has been reported as an inhibitor 
of miR-29 expression160, 169, 170. Nonetheless, the detailed regulatory mechanism behind 
miR-29 expression in CD4+ T cells remains unknown. Therefore, it is critical to identify 
the mechanism behind miR29 expression which can determine the fate of T helper cells 
by fine tuning the expression of its target genes. In this study, we hypothesized that 
Notch1 regulates Th1 differentiation by inhibiting miR-29 and resulting in de-repression 
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of its target genes ifng and tbx21. Thus, the second aim of this study is to determine if 
Notch1 can inhibit the expression of miR-29.  
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Figure 1.1: Different subsets of T helper cells 
CD4+ T cells can differentiate into multiple subsets upon activation in the presence of 
appropriate cytokine milieu. Each subset expresses a signature cytokine and lineage-
defining transcription factor. 
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Figure 1.2: Notch receptors 
Structural representation of mammalian Notch family of transmembrane receptors. Notch 
receptors 1-4 possess similar protein domain organization. The extracellular region of the 
receptors contain 29-36 epidermal growth factor (EGF) like repeats, three Lin12-Notch 
repeats (LNR) and heterodimerization domain. LNR and HD domain forms the negative 
regulatory region (NRR). The intracellular region of Notch contains the RBPj-associated 
molecule (RAM) domain, Ankyrin repeats, Notch cytokine response region, 
Transactivation domain (TAD) and a PEST sequence. It also contains a bipartite nuclear 
localization sequence (NLS). 
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Figure 1.3: Canonical Notch ligands 
Structural representation of canonical Notch ligands. Delta-like and Jagged family of 
ligands contain a N-terminal domain, DSL (Delta, Serrate, Lag2) domain, and EGF like 
repeats. DLL3 contains a DSL domain that has non-conserved cysteine spacing. Jagged 
family of ligands also contain a cysteine rich region. The intracellular portion of some 
ligands possess PSD-95/Dlg/ZO-1 ligand (PDZL) motif which plays a role independent 
of Notch signaling. 
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Figure 1.4: Non-canonical Notch ligands 
Structure and proposed function of non-canonical Notch ligands. The unique feature of 
non-canonical ligands is the absence of DSL domain. These ligands are structurally 
diverse and can be either membrane bound or soluble proteins. Ig-CAM 
(Immunoglobulin Cell adhesion molecule), FNIII (Fibronectin type III domain), GPI 
(glycophosphatidylinositol), FReD (Fibrinogen-related domain), DOS (Delta and OSM-
11), IGFBP (Insulin-like growth factor binding protein like domain), VWF-C (von-
Willebrand factor type C-like domain), TSP-1 (Thrombospondin type 1-like domain), 
CTCK (C-terminal cysteine knot domain), MBD (Matrix binding domain), RGD 
(Integrin binding motif), NT (N-terminal domain), CSD (Cold shock domain). *Only full 
length ligands were tested for binding, ** Jagged1 agonist, ***Jagged1 antagonist, 
****DLL4 agonist. (Adapted from D’Souza et al., 2010) 
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Figure 1.5: Overview of canonical Notch-signaling 
Notch receptors undergo proteolytic cleavage upon interaction with ligands at the cell 
surface. ADAM/TACE mediates the S2 cleavage which is immediately followed by -
secretase-mediated S3 cleavage. This results in release of NICD in the cytosol which 
eventually translocates to the nucleus where it interacts with CSL/RBPj inducing the 
expression of target genes.  
Notch 
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Figure 1.6: Ligand-independent activation of Notch signaling 
Mature Notch receptor gets internalized into early endosomes. The endocytosed receptor 
can be either transported to the cell surface or sorted to late endosomes. Notch receptor 
can undergo complete lysosomal degradation or retained at the limiting membrane of the 
late endosome where it undergoes partial degradation. The latter process leads to -
secretase mediated S3 cleavage and release of NICD into the nucleus. 
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Figure 1.7: Overview of non-canonical Notch signaling 
NICD can interact with several other proteins besides CSL. Non-canonical binding 
partners of NICD in the cytosol includes mTOR, Akt and β-catenin. In the nucleus it can 
interact with p50 and c-Rel sub-units of NF-B. 
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Figure 1.8: Post-translational modifications of N1-ICD 
Notch receptors undergo different post-translational modification (PTM). The 
extracellular domain of Notch has multiple glycosylation sites and is predominantly 
glycosylated. The intracellular domain undergoes different modifications which affects 
the stability and activity of the protein. (Adapted from Andersson et al., 2011)171 
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Figure 1.9: Notch induces differentiation of T helper cells 
Notch drives the differentiation of T helper cells by inducing the expression of a lineage 
defining transcription factor (iTreg) or by inducing both the transcription factor and the 
signature cytokine (Th1, Th2, Th9, and Th17). Notch promotes T follicular helper cells 
through an unknown mechanism.(Adapted from Amsen et al., 2015)136 
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Figure 1.10: microRNA biogenesis 
MicroRNAs are synthesized by RNA polymerase II as a longer transcript termed as 
primary miRNA (pri-miRNA). It undergoes endonuclear processing by Drosha to 
generate precursor miRNA (pre-miRNA). The pre-miRNA is transported by exportin V 
to the cytosol where it encounters another endonuclease Dicer and undergoes 
endonuclear digestion releasing mature miRNA. It binds to the 3’ UTR and loads the 
target mRNA onto RNA Induced Silencing Complex (RISC). 
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CHAPTER 2 
 
PHOSPHORYLATION OF NOTCH1 AND ITS EFFECTS DURING T CELL 
ACTIVATION AND DIFFERENTIATION 
 
2.1. Introduction 
The core components of Notch signaling include only a receptor, ligand and a DNA 
binding partner, but still it is a complex, context-dependent process. The intracellular 
domain of Notch (NICD) relays the signal and induces the transcription of its target 
genes. Notch receptors undergo a series of proteolytic cleavage events which culminates 
in the release of NICD. Notch is synthesized as a 300-350 kDa transmembrane protein 
and undergoes its first proteolytic cleavage (S1) in the Golgi by a furin like convertase at 
the HD domain creating the mature heterodimeric Notch receptor43, 172, 173. After S1 
cleavage, Notch receptors heterodimerize through HD-C and HD-N by non-covalent 
interactions to complete the maturation process. The mature receptors are transported to 
the cell surface where they interact with ligands. Binding of ligands causes a 
conformational change exposing the catalytic cleavage sites for ADAM10 and ADAM17 
at the NRR domain and triggers the S2 cleavage process in the juxta-membrane 
extracellular domain46. The resulting form of Notch is termed Notch extracellular 
truncation (NEXT). Interestingly, two different groups observed that the ligand-
dependent Notch cleavage is mediated by ADAM10 and ligand-independent cleavage is 
mediated by ADAM17172-174. Following S2 cleavage at V1711 (mNotch1), NEXT 
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undergoes intramembrane S3 cleavage within its transmembrane domain (V1744 in 
mNotch1) by -secretase complex, releasing NICD. Presenilin-1 and Presenilin-2 can 
physically interact with membrane and precursor forms of Notch1 and constitute the key 
molecules in the multiprotein (tetramer) -secretase complex173, 175. NICD possess two 
nuclear localization signals (NLS) that aid in translocation to the nucleus. 
In canonical Notch signaling, the S3 cleavage triggers NICD translocation to the nucleus 
where it interacts with CSL and MAML through its RAM domain and Ankyrin domain. 
Several reports have described that these proteins undergo a conformational change to 
assemble a transcriptionally active complex and trigger the transcription of Notch target 
genes. However, in non-canonical, ligand-independent Notch signaling, the inactive 
receptors are trafficked into the cytosol through endosomes77, 176. The acidic environment 
in the endosomes during trafficking dissociates the Notch heterodimer and triggers -
secretase mediated S3 cleavage. This releases NICD into the cytosol where it functions in 
a CSL-independent manner176-178.  
In CD4+ T cells, the activation of Notch signaling is proposed as a ligand-independent 
mechanism where TCR-mediated activation can lead to the release of NICD in the 
cytosol179. Subsequently, the released NICD plays a critical role in activation, 
proliferation and differentiation of T helper cell subsets136, 180. However, we do not know 
how NICD can perform such different roles at the same time. 
In this study, we demonstrate that Notch receptors are constitutively cleaved and it is 
independent of T cell activation. Additionally, we provide evidence that T cell activation 
leads to significant changes in the phosphorylation status of NICD and, therefore, its 
localization. Finally, we provide evidence that the soluble cytokines in the environment 
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induce changes in the phosphorylation status of Notch1. Moreover, we also identified that 
different cytokines can have different effects on the post-translational modification of 
NICD. 
2.2. Results 
2.2.1. Notch1 is constitutively cleaved and hyper-phosphorylated in unstimulated 
CD4+ T cells 
Intracellular Notch1 plays a crucial role in CD4+ T cell differentiation. Previous reports 
have indicated that there is an increased expression of N1-ICD upon T cell activation74. 
However, it is not clearly understood what leads to Notch1 cleavage upon TCR 
activation. To investigate Notch1 cleavage mechanism, we used two different antibodies 
that can detect different regions of cleaved Notch1. Cleaved Notch1 (Val1744) antibody 
detects the valine residue at the S3 cleavage site (Val1754 in humans and Val1744 in 
mice) and the monoclonal mN1a antibody detects the ANK-Notch Cytokine Response 
(NCR) region in N1-ICD. By intracellular staining using the clone mN1a, we did not 
detect any cleaved Notch1in unstimulated CD4+ T cells confirming previous reports 74 
(Figure 2.1). However, we identified N1-ICD around 125 kDa using cleaved Notch1 
(Val1744) antibody (Figure 2.2). Since, this is far higher than the predicted molecular 
weight (85 kDa), we wanted to determine if there are any post-translational 
modifications. Specifically, to determine if there is any phosphorylation of N1-ICD, the 
whole cell lysates were subjected to lambda phosphatase treatment. Upon phosphatase 
treatment, the molecular weight of N1-ICD was reduced to 110 kDa indicating that N1-
ICD is hyper-phosphorylated (Figure 2.2). Additionally, we did not observe any 
transmembrane Notch1 suggesting, that only cleaved Notch1 exists in unstimulated CD4+ 
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T cells. These results indicate that cleavage of Notch1 is not dependent on T cell 
activation and it exists in a constitutively cleaved and hyper-phosphorylated form. 
2.2.2. Release of N1-ICD is sufficient for phosphorylation 
Since N1-ICD is hyper-phosphorylated, we wanted to determine the cues that lead to this 
hyper-phosphorylation. CD4+ T cells were cultured under different polarizing conditions 
and the cells were harvested at 24 and 48 hours. By using a trans-membrane Notch1-
specific antibody we identified that full length Notch1 is not phosphorylated and this was 
confirmed by using lambda phosphatase treatment (Figure 2.3). Hence, to confirm if the 
expression of N1-ICD in the cytosol is sufficient for phosphorylation we over-expressed 
N1-ICD in DO11.10 T cell hybridoma cell line. This led to multiple forms of N1-ICD as 
observed in activated CD4+ T cells which, upon lambda phosphatase treatment, gave a 
single band of N1-ICD, suggesting N1-ICD is phosphorylated upon over expression 
(Figure 2.4). These results indicate that release of NICD into the cytosol leads to its 
phosphorylation. 
2.2.3. N1-ICD undergoes dephosphorylation upon TCR activation 
To determine if T cell activation affects phosphorylation of N1-ICD, we stimulated CD4+ 
T cells with plate bound anti-CD3 and anti-CD28 under Th0, Th1 or Th2 polarizing 
conditions and observed N1-ICD levels at 24, 48 and 72 hours. We observed different 
forms of N1-ICD at 24 and 48 hours around 117 kD and 112 kD. These different bands 
were confirmed as phosphorylated N1-ICD (pN1-ICD) by lambda phosphatase treatment 
(Figure 2.5). However, at 72 hours we identified completely dephosphorylated N1-ICD 
around 110 kD in addition to pN1-ICD at 117kD and 112kD. pN1-ICD in activated 
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CD4+ T cells appear at different reduced molecular weights (117 kDa, 112 kDa) 
compared to the hyper-phosphorylated N1-ICD (125 kDa) in the unstimulated CD4+ T 
cells (Figure 5). These data suggest that cleaved Notch1 undergoes a series of 
dephosphorylation events with time, upon T cell activation. Moreover, we did not find 
any difference in pNICD among Th0, Th1 or Th2 cells indicating that dephosphorylation 
of Notch1 is independent of T cell polarization. 
2.2.4. Phosphorylated N1-ICD is excluded from the nucleus 
The presence of multiple distinct versions of pN1-ICD prompted us to ask whether it 
affects N1-ICD sub-cellular localization. To determine the localization preference of 
NICD, we isolated cytosolic and nuclear extracts from activated CD4+ T cells at 48 and 
72 hours. We identified that phosphorylated NICD is present exclusively in the cytosol 
and dephosphorylated NICD is present both in the cytosol and the nucleus (Figure 2.6). 
These data suggest that phosphorylated residues of NICD potentially prevent its nuclear 
localization in T cells.  
2.2.5. Dephosphorylation of N1-ICD is independent of T cell activation 
Activation of TCR triggers a cascade of signaling events and results in the activation of 
different kinases and phosphatases involved in the pathway. Hence, we hypothesized that 
dephosphorylation of NICD requires TCR mediated activation of CD4+ T cells. To 
address the need for TCR activation, we performed a transwell assay whereby we can 
evaluate both the cells that received TCR-mediated activation and the cells that did not. 
The two sets of cells were separated by an insert with a membrane which is permeable 
only to soluble molecules. In this assay, we identified that the cells that did not receive 
TCR activation also have dephosphorylated N1-ICD (Figure 7). These data suggest, that 
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dephosphorylation of NICD is induced through soluble molecules, potentially by 
cytokines. 
2.2.6. IL-2, IL-4 and IL-7 induce differential dephosphorylation of N1-ICD 
The dephosphorylation of N1-ICD has been confirmed to be potentiated by cytokines. To 
identify the possible cytokines, we cultured CD4+ T cells with certain pro-survival 
cytokines IL-2, IL-4 or IL-7. Adding these exogenous cytokines led to a reduced 
molecular weight protein, consistent with dephosphorylated N1-ICD in unstimulated 
CD4+ T cells. However, the phosphatase treatment determined that N1-ICD still has 
phosphorylated residues and is not completely dephosphorylated. Interestingly, when the 
same blot was probed with mN1a clone, the effect of phosphatase treatment was observed 
only in the cells that were cultured in the presence of IL-2 or IL-4, but not in IL-7 (Figure 
2.8). This suggests that IL-7 treatment, in addition to dephosphorylating NICD, may also 
induce other post-translational modifications such as ubiquitination or acetylation. 
2.3. Discussion 
Even though the activation and post translational modifications of NICD have been 
studied over the years, we still do not clearly understand how these happen in CD4+ T 
helper cells. The most prevalent existing hypothesis for Notch activation in CD4+ T cells 
is through a ligand-independent pathway upon activation. However, our findings indicate 
for the first time that Notch1 is constitutively cleaved in CD4+ T cells. Interestingly, it 
was not detected by intracellular staining and only identified by western blotting at a 
significantly higher than predicted molecular weight. Here, we have confirmed using 
phosphatase assays that the increased molecular weight of N1-ICD is due to hyper-
phosphorylation upon S3 cleavage. Moreover, we have identified that only the cleaved 
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N1-ICD undergoes phosphorylation and the release of N1-ICD into the cytosol is 
sufficient for its phosphorylation. As reported earlier, phosphorylated N1-ICD is 
sequestered in the cytosol exclusively and our data confirm that this is the case in CD4+ T 
cells too.  
Also, in this study we have identified that Notch receptors can undergo 
dephosphorylation. The activation of TCR signaling pathway induces sequential 
dephosphorylation of the hyper-phosphorylated N1-ICD which culminates in nuclear 
localization of completely dephosphorylated N1-ICD. As N1-ICD can be cleaved through 
multiple other mechanisms, the hyper-phosphorylation of N1-ICD likely retains N1-ICD 
in the cytosol and prevents its nuclear activity in CD4+ T cells. The fact that only the 
dephosphorylated N1-ICD translocates to the nucleus, led us to believe that TCR 
activation is required for dephosphorylation. But, in contrast to our hypothesis we 
observed in a transwell assay that CD4+ T cells that received only the conditioned media 
from the activated T cells can induce dephosphorylation of N1-ICD. Moreover, resting 
the unstimulated CD4+ T cells with different exogenous survival cytokines led to 
dephosphorylation of N1-ICD in addition to other post translational modifications. This 
suggests that due to the involvement of Notch receptors in various physiological 
processes, the functional N1-ICD needs a ‘tag’ to perform the right function at the right 
time. Hence, N1-ICD may undergo differential post-translational modifications 
depending on the cytokine milieu.  
A recent study concluded that Notch was present on the promoters of ifng, il4 and gata3-
1a, irrespective of exogenous cytokines142, 181. However, the amount of Notch1 present on 
the promoter of il4 and Gata3-1a genes in Th1 cells was similar to Th2 cells142. This 
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finding indicates that the presence of Notch1 on the promoter alone is not sufficient to 
transcribe the Notch target genes. The lack of il4 and gata3-1a transcription in Th1 cells 
could be attributed to the potential differential post-translational modifications of NICD 
which need further study. Moreover, Milner and colleagues made a significant 
observation in myeloid cells, wherein the differentiation of 32D myeloid progenitor cells 
was regulated by exogenous cytokines, granulocyte–colony stimulating factor (G-CSF) or 
granulocyte–macrophage colony stimulating factor (GM-CSF)124. In this report, they 
identified a NCR domain next to the Ankyrin repeats and determined that NCR is 
responsible for cytokine specific differentiation response and nuclear localization. It 
remains to be determined if that same phenomenon can occur in CD4+ T cells as well. 
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Figure 2.1: Activation of Notch1 in CD4+ T cells  
CD4+ T cells were isolated from C57BL/6 mice using BD Imag beads. Intracellular 
staining for cleaved Notch1 was done for (a) unstimulated or (b) CD4+ T cells stimulated 
with anti-CD3 and anti-CD28 for 24 hours. (c) Mean fluorescence intensity for cleaved 
Notch1 was determined for unstimulated and stimulated CD4+ T cells. n=3. *=p<0.05, 
**=p<0.01, ***=p<0.001, ****=p<0.0001  
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Figure 2.2: Notch1 is constitutively cleaved and hyper-phosphorylated in 
unstimulated CD4+ T cells 
CD4+ T cells were isolated from C57BL/6 mice using BD Imag beads. Lysates were 
subjected to mock or lambda phosphatase treatment and western blot was performed for 
transmembrane (TM) and cleaved Notch1 on unstimulated CD4+ T cells. Cleaved Notch1 
appears at higher than the predicted molecular weight (~85kDa) and lambda phosphatase 
treatment decreases the molecular weight suggesting it is hyper-phosphorylated. Vinculin 
was used as the loading control. 
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Figure 2.3: Mature full-length Notch1 does not undergo phosphorylation. 
CD4+ T cells were isolated from C57BL/6 mice and activated under different 
polarizing conditions. Lysates were subjected to mock or lambda phosphatase 
treatment and western blot analysis was performed to detect Notch1 in 
unstimulated cells, 24 and 48 hours post-activation under Th0, Th1, or Th2 
polarizing condition. The blot was probed with trans-membrane (TM) Notch1 
specific antibody (D1E11). Lambda phosphatase treatment did not decrease the 
molecular weight of trans-membrane Notch receptor. 
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Figure 2.4: Notch1 intracellular (N1-ICD) domain is constitutively phosphorylated. 
DO11.10 hybridoma cell lines were transduced by retrovirus with or without N1-ICD-
expressing constructs. Lysates were subjected to mock or lambda phosphatase treatment 
and western blot analysis was performed to detect cleaved Notch1 in empty vector (EV) 
or N1-ICD over-expressing cell lines. Tubulin was used as the loading control. Over-
expression of N1-ICD in DO11.10 cell lines led to its phosphorylation as observed by its 
increase in molecular weight and lambda phosphatase treatment decrease the size 
confirming its phosphorylation. 
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Figure 2.5: Notch1 undergoes dephosphorylation upon activation of CD4 T cells. 
CD4+ T cells were isolated from C57BL/6 mice and activated under different polarizing conditions. Lysates were subjected to 
mock or lambda phosphatase treatment and western blot analysis was performed for lysates obtained from unstimulated cells 
(UNS), 24, 48 and 72 hours post activation under Th0, Th1 or Th2 polarizing condition. The blot was probed with cleaved 
Notch1 antibody (Val1744). Different forms of N1-ICD were observed at a lower molecular weight compared to unstimulated 
CD4+ T cells suggesting that hyper-phosphorylated N1-ICD may have been dephosphorylated after T cell activation. 
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Figure 2.6: Phosphorylated N1-ICD is present exclusively in the cytosol. 
CD4+ T cells were isolated from C57BL/6 mice and activated with anti-CD3 and 
anti-CD28. Western blot analysis was performed on cytosolic (Cyt) and nuclear 
(Nuc) extracts obtained from cells activated for 24 and 48 hours. The blot was 
probed with cleaved Notch1 (Val1744) antibody. The phosphorylated high 
molecular weight N1-ICD was found exclusively in the cytosol. Tubulin is used 
as a control for cytosolic extract. 
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Figure 2.7: Phosphorylation status of N1-ICD is independent of TCR activation. 
CD4+ T cells were isolated from C57BL/6 mice and cultured in a transwell chamber. The 
cells were cultured in the presence of plate-bound anti-CD3 and anti-CD28 or cultured 
in the insert. Western blot analysis of the lysates obtained from the cells grown in the 
insert at 24 and 48 hours post-activation. The blot was probed with cleaved Notch1-
specific antibody (Val1744). N1-ICD is phosphorylated in the absence of TCR mediated 
activation. 
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Figure 2.8: Dephosphorylation of N1-ICD can be induced by survival cytokines. 
CD4+ T cells were isolated from C57BL/6 mice and cultured in the presence of IL-2, IL-4 
or IL-7 for 24 hours. Lysates were subjected to mock or lambda phosphatase treatment 
and western blot analysis was performed on the lysates obtained from the cells cultured 
for 24 hours with respective cytokines. The blot was probed with cleaved Notch1-specific 
antibodies Val1744 (Top) or mN1a (bottom). Different cytokine treatments led to 
different phosphorylation patterns of N1-ICD as seen above. 
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CHAPTER 3 
 
NOTCH1 MEDIATED REGULATION OF MIR-29 ALTERS THE 
PROINFLAMMATORY CYTOKINES AND TH1 RESPONSE 
3.1. Introduction 
Naïve CD4+ T cells can be activated in response to encountering antigens. Upon 
activation, these cells will proliferate and differentiate into specific T helper cell subset 
directed by the cytokines present in the environment. Based on the expression of unique 
transcription factors and characteristic cytokines, Th cells can be broadly categorized into 
defined subsets with Th1, Th2, Th17, iTreg and Tfh being the most studied to date
1. For 
Th1 cells, the transcription factor T-bet is a critical regulator of cell fate and its expression 
ultimately leads to production of IFN, a signature Th1 pro-inflammatory cytokine1. T-bet 
is a direct transcriptional target of the transmembrane receptor Notch1, controlled by 
canonical Notch signaling during Th1 differentiation
140. 
The Notch family of transmembrane receptors, can be activated by its ligands Delta-like 
(DLL)-1,3,4 and Jagged (Jag)-1,2. Notch signaling plays an important role in cell fate 
determination. There are four Notch receptors (1-4) expressed in mammalian cells, 
however, only the expression of Notch1-3 has thus far been described in T cells180. Upon 
interaction with cognate ligands, Notch receptors undergo a series of proteolytic cleavage 
events. The final S3 cleavage is mediated by gamma secretase complex and generates the 
transcriptionally active Notch intracellular domain (NICD)173. NICD can translocate to 
the nucleus and interact with its DNA binding partner CBF1-Suppressor of Hairless-Lag1 
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(CSL)41. Notch binding to CSL results in further recruitment of transcriptional co-
activators like mastermind like (MAML-1) and p300136. CSL-dependent Notch signaling 
is referred to as canonical Notch signaling. There are also reports indicating NICD can 
interact with proteins other than CSL, both in the nucleus and cytosol, to signal through 
non-canonical mechanisms179.  
Multiple reports have identified a crucial role for Notch signaling in Th cell 
differentiation either through canonical or non-canonical signaling136, 179. One of the first 
studies implicating Notch1 in Th1 differentiation, demonstrated that blocking the actions 
of gamma secretase to prevent Notch cleavage attenuates the expression of T-bet and 
IFN in developing Th1 cells140. Expression of such lineage defining transcription factors 
and proinflammatory cytokines has to be tightly regulated. In the case of Th1 cells, 
dysregulated IFNγ expression can lead to chronic autoimmune disorders by exerting its 
effects on other immune cells, resulting in a hyper-immune response182. Hence, there are 
various cell intrinsic mechanisms that have evolved to regulate the expression of 
proinflammatory cytokines and transcription factors.  
miRNAs are short single stranded non-coding RNAs that act as a post transcriptional 
regulators of gene expression. They silence their target mRNAs through complementary 
base pairing and forming RNA induced silencing complex (RISC)153. Based on their 
complementarity, the target mRNA can either be degraded or its translation into protein is 
greatly reduced. The miR-29 family of miRNA consists of miR-29 a, b and c which are 
classified based on their seed sequence183. They can directly target the mRNA of Th1 
signature molecules ifng and tbx21160, 162. Interestingly, in response to increased 
exogenous IFN, miR-29 expression increases, thereby forming a negative feedback 
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loop168. In memory T cells of patients with multiple sclerosis, which displays an active 
Th1 response, more than two fold increase in miR-29b was observed, consistent with this 
negative feedback loop168. Furthermore, NF-B, a non-canonical binding partner of 
Notch, can also inhibit the expression of miR-29, indicating that miR-29 expression is 
likely regulated through multiple mechanisms160, 170. 
We previously showed Notch1 signaling contributes to Th1 differentiation, including 
regulation of T-bet and IFN production140. Here, we investigated whether Notch1 also 
primes CD4+ T cells for Th1 differentiation by affecting the expression of miR-29. In this 
study, we demonstrated that Notch1 can inhibit the expression of miR-29 in Th1 cells. 
Furthermore, we show that Notch1 represses miR-29 through an NF-B-independent, 
CSL-mediated canonical signaling mechanism. However, we also found that the early 
repressive effects of Notch1 is masked by IFN-induced expression of miR-29 during the 
later stages of Th1 differentiation. Thus, we have identified a mechanism by which 
Notch1 and IFN may act in opposition to maintain a balance of miR-29 expression.  
3.2. Results 
3.2.1. -Secretase-mediated inhibition of T-bet is post transcriptional 
Signaling through the Notch1 intracellular domain (N1-ICD) is important in the 
differentiation of multiple T helper cell subsets. We previously demonstrated a cell-
intrinsic role for Notch1 in Th1 differentiation and that both tbx21 and ifng are 
transcriptional targets of Notch1140. In addition, T-bet expression in Th1 cells can also 
occur in the absence of the canonical Notch1 binding partner, CSL184. To further 
investigate the detailed mechanism behind Notch1-mediated Th1 differentiation, we 
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focused on Notch1-mediated regulation of miR-29 in Th1 cells. We began by using a 
novel gamma secretase inhibitor (GSI) PF-03084014, currently in Phase 1 clinical trials 
to treat patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic 
lymphoma185. This novel GSI prevents the intramembranous cleavage of Notch at the S3 
site and hence the release of active NICD. We cultured CD4+ T cells, isolated from bulk 
splenocytes, under Th1 polarizing condition for 4 days. We used an optimal 
concentration (25µM) of GSI that inhibits the cleavage of Notch1, which is maximally 
expressed 48 hours after stimulation (Fig 3.1A). Inhibiting -secretase, reduced 
expression of T-bet as we had shown before (Fig 3.1B) but, surprisingly, we found the 
transcript levels of tbx21 were higher than vehicle-treated controls. Specifically, by 24 
hours after activation, the GSI-treated samples showed almost 2-fold increase in tbx21 
transcripts compared to controls (Fig 3.1D) while protein expression remained lower than 
vehicle treated controls. These data suggested that Notch signaling may regulate T-bet 
expression by post-transcriptional mechanism. 
3.2.2. GSI-mediated inhibition of Notch leads to increased expression of miR-29 at 
early time points during Th1 differentiation but not at later time 
To determine, whether Notch can inhibit miR-29 expression in murine Th1 cells and 
regulate expression of T-bet, we treated CD4+ T cells with DMSO or GSI and then 
further cultured the cells under Th1 polarizing condition for 4 days. GSI treatment de-
repressed miR-29b expression within the first 24 hours, while miR-29a and miR-29c 
were less affected (Fig 3.2A). Following 96 hours of polarization, vehicle treated Th1 
cells expressed higher levels of all three family members compared to GSI treated cells 
(Fig 3.2B). This suggested that miR-29 levels may be regulated differently during early 
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and later stages of Th1 differentiation. In particular, the contradictory data obtained at 
later stages could be because of an indirect effect of inhibition of Notch because it has 
been shown that IFN can induce the expression of miR-29168. 
3.2.3. IFN masks the effect of Notch1 on miR-29 at later stages 
It has been reported that STAT1 can directly induce the expression of miR-29 through 
activation of IFN signaling and forming a negative feedback loop168. Notch1 induces 
IFN expression in samples not treated with GSI. Therefore, we hypothesized that IFN-
STAT1 signaling might be “eclipsing” any Notch1-mediated repressive effects on miR-
29 expression. To address the potential hierarchical regulation of miR-29 by IFN over 
Notch1, we pretreated CD4+ T cells with DMSO or GSI and cultured them for 4 days 
under neutral, non-polarizing conditions in the presence or absence of IFN-neutralizing 
antibody for 48 hours. We observed that blocking IFN signaling reduced miR-29 
expression as was previously reported168. Interestingly, when we neutralized the effects 
of IFN on miR-29, we observed that GSI-treated samples have significantly higher 
levels of miR-29 expression compared to anti-IFN treated cells cultured in DMSO (Fig 
3.3A). To further investigate the simultaneous opposing effects of IFN and Notch1 on 
miR-29 expression in Th1 cells, we sought to ask if Notch can repress miR-29 expression 
in the absence of IFN signaling. We cultured CD4+ T cells under Th1 polarizing 
conditions for 48 hours. After this activation period, we lifted cells and re-cultured them 
in fresh media for an additional 48 hours in the presence of DMSO or GSI. Under these 
conditions, in which the effect of exogenous IFN signaling on Th1 cells is minimized, 
we observed there was little to no expression of miR-29 in our DMSO-treated samples 
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(Fig 3.3B). In contrast, we noted consistently higher levels of miR-29 in Th1 cells treated 
with GSI further supporting the notion that Notch signaling represses miR-29. 
Altogether, this data provides evidence that miR-29 expression is tightly regulated by 
Notch1-mediated inhibition and IFNγ-mediated induction, to fine-tune Th1 polarization. 
To further confirm the effects of IFNγ and Notch on miR-29 regulation, CD4+ T cells 
were cultured under Th2 polarizing condition for 4 days. We observed that GSI-mediated 
inhibition of Notch signaling leads to increased miR-29 expression in Th2 cells (Fig 3.4). 
These data confirms that Notch1 suppresses miR-29 and its effect can be masked IFNγ- 
mediated induction. 
3.2.4. Notch1 directly represses miR-29 expression 
Multiple studies have reported that miR-29 regulates the levels of IFN and T-bet by 
directly targeting transcripts of their respective genes ifng and tbx21160, 162, 168. Since our 
previous studies have shown that Notch1 can regulate IFN expression directly, as well 
as indirectly by modulating the expression of T-bet, we asked whether Notch1 can alter 
the expression of tbx21 by inhibiting miR-29. To test this hypothesis and to confirm it is 
Notch1 that represses miR-29 and not another substrate of -secretase, we used the 
DO11.10 T cell hybridoma cell line retrovirally transduced either with an empty vector 
(EV) or with a construct encoding residues 1757-2555 of the human Notch1 intracellular 
domain (N1-ICD). Over-expressing N1-ICD led to a significant reduction in the mature 
transcript of all miR-29 family members.(Fig 3.5A). We next used a luciferase construct 
with a validated miR-29b1a promoter sequence169, to address whether Notch1 may be 
regulating miR-29 expression by reducing its promoter activity. Expressing the miR-
29b1a luciferase construct, together with N1-ICD in 3T3 cells robustly decreased 
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luciferase expression, suggesting that N1-ICD can repress the promoter activity of miR-
29 (Fig 3.5B). Collectively, these data support the hypothesis that Notch1 can regulate 
tbx21 expression by inhibiting miR-29.  
3.2.5. Notch1-mediated inhibition of miR-29 is NF-B independent 
To further elucidate the mechanism behind Notch1 mediated repression of miR-29, we 
focused on NF-B, which is a non-canonical binding partner of Notch1 and is known to 
suppress miR-29 expression. We treated DO11.10-EV and DO11.10-N1-ICD cell lines 
with a pharmacological inhibitor of NF-B, Bay11-7085 (5µM), which acts to 
irreversibly inhibit phosphorylation of IB. Consistent with previous reports, we 
observed increased miR-29 expression in DO11.10-EV cells treated with Bay11-7085 
(Fig 3.6). Surprisingly, in DO11.10 cells that constitutively express N1-ICD (DO11.10-
N1ICD), inhibiting NF-B with Bay11-7085 did not affect miR-29 expression. Overall, 
these data suggest that Notch1-mediated repression of miR-29 is independent of NF-B 
signaling. 
3.2.6. Canonical Notch1 signaling represses miR-29 upregulation 
Within the promoter of several Notch-regulated genes, CSL binding sites have been 
found to be “nested” within larger NF-B response elements 186. In a recent report, 
mutating one of two NF-B binding sites within the miR-29 promoter was shown to 
result in miR-29 derepression160. Closer examination revealed that this mutated NF-B 
site also contained a nested CSL binding site. To analyze miR-29 regulation by canonical 
Notch1 signaling we performed chromatin immunoprecipitation assays using anti-CSL or 
anti-Notch1 antibody. This revealed that both CSL and Notch1 binds to this nested CSL 
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binding site. To further confirm the role of canonical Notch signaling in regulation of 
mIR-29, we over-expressed in NIH3T3 cells, MAML1 or dominant-negative MAML1 
(DN-MAML1), together with N1-ICD and a luciferase construct driven by the miR-
29ab1 promoter. We observed that over-expressing N1-ICD alone or with MAML1 
decreased the promoter activity of miR-29ab1. By contrast, over-expressing DN-
MAML1 together with N1-ICD reversed Notch1-mediated repression of miR-29ab (Fig 
3.7). Overall, these data suggest that Notch1 represses miR-29 expression by reducing its 
promoter activity through a CSL-dependent, canonical Notch signaling mechanism. 
3.3. Discussion 
Multiple reports have identified that miRNAs play a critical role during immune 
responses, including during T cell proliferation and differentiation. However, how these 
miRNAs, themselves, are regulated is not well-characterized. In this report, we 
investigated a role for Notch1 signaling in regulating miR-29, a miRNA known to 
modulate expression of IFN and T-bet. We have previously demonstrated that Notch1 
influences T helper cell differentiation and regulates IFN and T-bet in Th1 cells 140, 187. 
This led us to the further investigate whether Notch1 might also contribute to Th1 
differentiation through its effects on miR-29 expression. Using both pharmacological and 
genetic approaches, we show that Notch1 can repress miR-29 in a CSL-dependent 
manner during early stages of Th1 cell differentiation and thus, prime CD4
+ T cells for 
Th1 differentiation. 
Pretreating CD4+ T cells with the novel gamma secretase inhibitor PF-03084014, to 
inhibit Notch signaling during Th1 polarization, decreased expression of T-bet and IFN 
consistent with previous studies. However, the transcript levels of tbx21 were 
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significantly higher in cells pre-treated with GSI at 24 hours, than in DMSO-treated cells 
harvested at the same time point. This suggested to us that post-transcriptional regulation 
of tbx21 may be at work during early stages of Th1 differentiation. Simultaneously, we 
also observed increased expression of miR-29 while inhibiting Notch signaling, further 
confirming our conclusion. Since GSI treatment can also affect other cellular substrates 
of gamma secretase, including other Notch family members and Notch ligands, we over-
expressed Notch1 intracellular domain in different cell lines to conclusively show that 
Notch1 can repress miR-29. From our study, we conclude that miR-29 exerts its effects 
on tbx21 expression by inhibiting its translation. However, a previous study has indicated 
miR-29 regulates the expression of tbx21 by destabilization and degradation of the 
transcript. This could simply be a result of over-expression of miR-29 and may not reflect 
the actual physiological condition. Another possible reason for the contradictory data 
could be, miR-29 inhibits translation of tbx21 before inducing degradation as observed 
for miR-430 targets by ribosome profiling during zebrafish development 188.  
However, in polarization assays we observed opposing effects at early and later stages of 
differentiation. Since IFN can induce the expression of miR-29 and trigger a negative 
feedback loop, it is possible that Notch-mediated effects are “eclipsed” by IFN 
signaling. By blocking IFN signaling and removing IFN from extracellular 
environment we were able to show that IFN indeed masks the repressive effects of 
Notch1. This suggests that Notch1 may inhibit the expression of miR-29 at the early 
stages of activation when IFN is absent and primes the immune system to mount an 
effective Th1 response. IFN in turn, triggers the expression of miR-29 at later stages of 
differentiation and further regulates proinflammatory responses. Therefore, we conclude 
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that Notch1 and IFN may act as a “yin and yang” of miR-29 regulation to fine tune Th1 
responses. 
In CD4+ T cells, miR-29 expression has been shown to be inhibited by NFB, a non-
canonical binding partner of Notch1. However, our study revealed that Notch1represses 
miR-29 through a NF-B-independent pathway. Notch1 lacks a DNA binding domain 
and needs a chromatin binding partner to regulate the transcription of its target genes. In 
addition to c-Myc, YY1 and hedgehog binding sites 169, 170, the miR-29 promoter also has 
a putative CSL binding site nested in the NFB binding sequence. By using a dominant 
negative mutant of a CSL-dependent transcriptional activator MAML1, we identified that 
Notch1 represses miR-29 through canonical signaling. Similar to NFB, Notch-CSL 
complex is mainly known to act as a transcriptional activator. However, previous studies 
have reported both NFB and Notch-CSL complex can form a transcriptional repression 
complex through their interaction with HDAC proteins and YY1 respectively. 
Furthermore, Notch has been shown to repress Ccr9 transcription by inhibiting the 
recruitment of the histone acetyl transferase p300 to the enhancer region189. It has to be 
noted that Notch-CSL-MAML1 complex recruits p300 to form a ternary complex at the 
binding site. Hence, it is possible that by recruiting p300 to form the canonical signaling 
complex, Notch1 prevents p300 to function in the enhancer region. Therefore, Notch1 
may repress miR-29 either directly through its interaction with a binding partner or 
indirectly by sequestering a transcriptional co-activator like p300. In addition, Notch1 
may also inhibit mir-29 expression through canonical Notch signaling targets like Hes1. 
In conclusion, in this report we have identified that Notch1 represses the expression of 
miR-29 through a CSL-dependent canonical Notch signaling. However, further studies 
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are needed to determine how Notch-CSL-MAML1 complex function to repress miR-29. 
In resting memory cells of multiple sclerosis patients, transcriptional regulation of miR-
29 has been found to be impaired168. Hence, it is extremely important to elucidate the 
complete mechanism behind transcriptional repression of miR-29. This would provide us 
an opportunity to develop novel therapies for Th1-mediated diseases focusing on 
miRNAs instead of Notch1 which is involved in a plethora of cellular processes. 
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Figure 3.1: Gamma secretase mediated regulation of T-bet expression is post transcriptional. 
CD4+ T cells isolated from C57BL/6 mice were pretreated with DMSO or GSI for 30 minutes and stimulated with plate-bound anti-
CD3 and anti-CD28 under Th1 polarizing conditions for 48 hours (A) or indicated time (B-E). (A) Western Blot for cleaved Notch1 
(Val1744) and vinculin as loading control. Mean fluorescent intensity (MFI) values were plotted for (B) T-bet and (C) IFN. Total 
RNA was extracted and relative expression of (D) tbx21 and (E) ifng transcripts normalized to expression of b-actin. Fold changes are 
determined relative to unstimulated CD4+ T cells. Results are representation of three independent experiments.
DMSO  GSI 
IFN 
55 
 
_ 
 
 
 
 
Figure 3.2: GSI-mediated inhibition of Notch leads to increased expression of miR-
29 at earlier time intervals but not at later time intervals in Th1 cells. 
CD4+ T cells isolated from C57BL/6 mice were pretreated with DMSO or GSI for 30 
minutes and stimulated with plate-bound anti-CD3 and anti-CD28 under Th1 polarizing 
conditions. Total RNA was extracted at 24 hours (A) or indicated time intervals (B). The 
relative expression of miR-29 a, b and c, normalized to expression of sno202. Fold 
changes are determined relative to unstimulated CD4+ T cells. Results are the mean of 
triplicate wells + S.D and are representative of three independent experiments. Statistical 
analysis were performed using unpaired t test. *p<0.05 
  
_
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Figure 3.3: IFN masks the effects of Notch on miR-29 expression. 
CD4+ T cells isolated from C57/BL6 mice were directly stimulated with plate bound anti-
CD3 and anti-CD28 under Th1 polarizing condition (A) or pretreated with DMSO or GSI 
for 30 minutes before stimulation  and cultured with or without Ifn blocking antibody 
(B). (A) Cells were harvested after 48 hours and cultured using fresh media with DMSO 
or GSI for another 48 hours. (B) Cell were harvested after 72 hours of stimulation. Total 
RNA was extracted and relative expression of miR-29 a, b and c normalized to 
expression of sno202. Fold changes are expressed relative to unstimulated CD4+ T cells. 
Results are the mean of triplicate wells + S.D and are representative of three independent 
of experiments. Statistical analysis were performed using two way ANOVA, with 
Tukey’s multiple comparisons test applied.  *p<0.05, **<p0.01, ***p<0.001, p<0.0001  
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Figure 3.4: GSI-mediated inhibition of Notch leads to increased expression of miR-
29 in Th2 cells. 
CD4+ T cells isolated from C57BL/6 mice were pretreated with DMSO or GSI for 30 
minutes and stimulated with plate bound anti-CD3 and anti-CD28 under Th2 polarizing 
conditions. Total RNA was extracted at indicated time intervals. The relative expression 
of miR-29 a, b and c was normalized to expression of sno202. Fold changes are 
determined relative to unstimulated CD4+ T cells. Results are the mean of triplicate wells 
+ S.D. Statistical analysis were performed using two way ANOVA, with Tukey’s 
multiple comparisons test applied.  *p<0.05, **<p0.01 
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Figure 3.5: Notch1 inhibits the expression of miR-29. 
DO11.10 T cell hybridoma stably transduced with empty vector or Notch1-intracellular 
domain and total RNA was extracted. (A) The micro RNAs were reverse transcribed with 
respective stem loop primers and relative expression of miR-29a, b and c normalized to 
expression of sno202. Fold changes are expressed relative to DO11.10-EV cells. (B) 
NIH3T3 cell lines were transfected with indicated expression vectors and pRL-CMV. 
Relative firefly luciferase activity of a construct containing miR-29ab1 promoter was 
measured and normalized to renilla luciferase expression. Results are the mean 
expression + S.D. of three independent experiments. Statistical analysis was performed 
using unpaired t test. * p<0.05. 
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Figure 3.6: Notch1 mediated inhibition of NF-B independent 
DO11.10 T cell hybridomas stably transduced with empty vector or Notch1 intracellular 
domain were treated with DMSO or Bay11-7085 for 24 hours. Total RNA was extracted 
and relative expression of miR-29 a, b and c normalized to expression of sno202. Fold 
changes are expressed relative to unstimulated CD4+ T cells. Results are the mean of 
three independent of experiments + S.D. Statistical analysis were performed using two 
way ANOVA, with Tukey’s multiple comparisons test applied.  *p<0.05 
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Figure 3.7: Notch1 inhibits miR-29 expression through canonical signaling 
NIH3T3 cell lines were transfected with indicated expression vectors (A,B) and pRL-
CMV. Relative firefly luciferase activity of a construct containing the miR-29ab1 
promoter was measured and normalized to renilla luciferase expression. Results are 
representative of three independent experiments. (C.) Chromatin Immunoprecipitation of 
CD4+ T cells activated for 72 hours. Anti-CSL and Anti-Notch1 was used to precipitate 
the respective proteins bound to DNA. DNA in complex was amplified with primers 
specific for CSL binding region in miR-29 promoter. Densitometric values were 
normalized to the input control using the ImageJ software. 
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CHAPTER 4 
 
OVERALL PERSPECTIVES AND FUTURE DIRECTIONS 
This doctoral research work is aimed towards better understanding of Notch signaling 
and its effects on CD4+ T cell differentiation. Notch signaling is at the center of various T 
helper cell differentiation pathways. However, we do not know how Notch drives 
opposing differentiation programs at the same time. Our observation of the existence of 
cleaved Notch1 in naïve CD4+ T cells makes is an intriguing one. We found that Notch1 
is constitutively cleaved and hyper-phosphorylated in naïve cells. An interesting 
discovery made by Radtke and colleagues might pave way for solving the mystery behind 
this constitutive cleavage of Notch1 in naïve cells190. Fibroblast-like stromal cells are 
required for tissue architecture in secondary lymphoid organs like spleen and lymph 
node. It was identified that deletion of Notch ligands in stromal cells causes impaired 
differentiation of follicular helper T cells, indicating that Notch receptors in CD4+ T cells 
and its ligands on stromal cells may interact190. Therefore, the ligands present on stromal 
cells or APCs in the secondary lymphoid organs could trigger the cleavage and result in 
phosphorylated Notch1 CD4+ T cells. We need to determine, if the ligands present in the 
stroma of spleen and lymph node are activating Notch signaling by using similar ligand 
deficient animals190. However, TCR-mediated activation alters the phosphorylation state, 
probably due to dephosphorylation. Several kinases have been identified to phosphorylate 
Notch1 and regulate its function but we do not know what, if any phosphatases act on 
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Notch1. Therefore, more careful studies need to be done to validate whether the changes 
in phosphorylation status is due to dephosphorylation as opposed to phosphorylation of 
newly synthesized Notch receptors. To address this question, the phosphorylated sites of 
Notch1 in CD4+ T cells need to be determined before and after activation.  
The difference in phosphorylation status of N1-ICD is fascinating also because of the 
numerous phosphatases that gets activated and contributes to T cell activation. This 
includes several protein tyrosine phosphatases like CD45, SHP2 and several MAP kinase 
phosphatases (MKP)191, 192. Interestingly, the MAP kinase phosphatases (MKP) have 
been identified as enzymes with dual specificity towards both tyrosine and threonine193, 
194. Specifically, MKP-1 deficient animals have been shown to exhibit resistance towards 
experimental autoimmune encephalomyelitis (EAE), an autoimmune disease mediated by 
Th1 and Th17 response
195. Phosphatase and tensing homolog (Pten) and Notch signaling 
has been shown to play an important role in differentiation of retinal progenitor cells 
(RPCs). In Pten deficient cells, NICD fails to form a transcriptional activator complex 
and causing premature differentiation of RPCs95, 196. So, it is possible that a similar 
mechanism may exist in CD4+ T cells to modulate the activity of Notch receptors. 
N1-ICD has multiple sites for several post-translational modifications such as 
phosphorylation, ubiquitination, and acetylation. Different forms of phosphorylated 
Notch1 can potentially have different functions because we identified only N1-ICD 
devoid of any phosphorylation in the nucleus. However, in the cytosol we detected 
multiple forms of phosphorylated N1-ICD. Hence, this could be a possible mechanism 
through which Notch1 can be involved in different signaling pathways at the same time. 
Moreover, we discovered that soluble cytokines triggered the alteration in 
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phosphorylation state of N1-ICD. Further analysis revealed that culturing unstimulated 
CD4+ T cells in the presence of different T cell survival cytokines induced different post 
translational modification. Similarly, different proinflammatory cytokine signaling 
pathways could induce different modifications to Notch1 directing it to perform 
appropriate and distinct functions. This theory was further supported by the presence of 
Notch1 on the gata3 and il4 promoter during Th1 differentiation
142. However, just the 
presence of Notch1 on the promoter did not initiate the transcription of respective genes. 
This lack of transcription could be attributed to the absence of a required post-
translational modification to direct Notch1-mediated transcription. Hence, a detailed 
investigation of different post-translational modifications of Notch1 would further clarify 
whether these modifications can regulate its function and ability to interact with different 
partners. 
In addition to regulating the expression of signature molecules of T helper cell subsets, 
we have identified that Notch1 can also repress miR-29, which targets ifng and tbx21 
(Figure 5.1). This suggests that N1-ICD acts as a signaling hub and regulates the 
expression of multiple molecules to program T helper cells towards Th1 differentiation. 
Here we report that N1-ICD-mediated repression of miR-29 is independent of NFB and 
it is achieved through the canonical signaling pathway. However, we do not yet fully 
understand what causes the Notch1-CSL-MAML1 complex to inhibit miR-29 expression. 
YY1 is another transcription factor that has been identified as a repressor of miR-29 in 
myoblasts170. Therefore, a potential mechanism could be through YY1 since Notch1-CSL 
complex has been shown previously to act as a repressor in conjunction with YY1 by 
forming a high molecular weight complex197. However, mutation studies of YY1 binding 
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sites in miR-29 promoter indicated, that in CD4+ T cells miR-29 repression could be 
independent of YY1160. Analyzing YY1 binding sites further upstream of the miR-29 
promoter is needed to appreciate the role of YY1 more conclusively. Canonical Notch 
signaling has been shown to repress the transcription of Ccr9 gene by preventing the 
binding of p300 to the enhancer region189. This provides a possible alternative 
mechanism by which Notch1-CSL-MAML1 complex represses the transcription of miR-
29. Therefore, studying the role of transcriptional activators like p300 is crucial to 
completely elucidate the mechanism behind canonical Notch signaling-mediated 
repression of miR-29. 
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   A.  
B. 
Figure 4.1: Schematic representation of Notch mediated regulation of 
miR-29 and Th1 differentiation. 
Notch1 facilitates Th1 differentiation by inhibiting miR-29 (A.), which targets 
the Th1 signature molecules, ifng and tbx21 through CSL-dependent canonical 
Notch signaling. (B.) By inhibiting miR-29 and inducing the expression of 
IFN and T-bet, Notch1 enables the immune system to mount effective Th1 
response. 
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CHAPTER 5 
 
MATERIALS AND METHODS 
5.1. Materials 
5.1.1. Mice 
C57BL/6J mice were purchased from Jackson laboratories (Bar Harbor, ME) and were 
bred, housed and utilized in accordance with guidelines approved by the Institutional 
Animal Care and Use Committee of the University of Massachusetts-Amherst. Mice aged 
8-12 weeks were used for all the experiments. 
5.1.2. Plasmids and Cell lines 
The pGL3-miR29b1a promoter vectors were a kind gift from J. Mott169. The N1-ICD 
parental pcDNA3 expression plasmids were a kind gift from A.Capobianco198 and 
subsequently cloned into pEGFP vector as described75. MAML-1 and DNMAML-1 
vectors were a kind gift from L. Miele and generated as described199. Generation of 
DO11.10 T cell hybridoma cell lines with empty vector or N1-ICD were described 
previously75. 
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Table: 5.1. Commercial Reagents and Kits 
Product Catalog No Vendor 
Anti-Mouse CD4 Magnetic Particles 551539 BD Biosciences 
BD Golgi stop 554724 BD Biosciences 
Protease inhibitor cocktail B14001 Bimake 
Phosphatase inhibitor B15001 Bimake 
2X SYBR Green qPCR Master Mix B21203 Bimake 
PCR Purification Kit 9K-006-0001 Biobasic 
Clarity ECL 1705060 Biorad 
FoxP3/Transcription factor staining Buffer Set 00-5523-00 eBioscience 
PF-03084014 HY-15185 MedChem Express 
Lambda protein phosphatase P0753S New England Biolabs 
MuLV Reverse Transcriptase M0253L New England Biolabs 
Recombinant RNasin Ribonuclease Inhibitor N2515 Promega 
Dual Luciferase Reporter Assay E1910 Promega 
Protein A/G PLUS-Agarose SC-2003 Santa Cruz 
Biotechnology 
Bay11-7085 B5681 Sigma 
NE-PER Nuclear and Cytoplasmic Extraction 
Reagents 
78833 ThermoFisher 
Scientific 
Quick-RNA MiniPrep R1055 Zymo Research 
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Table: 5.2. Antibodies and Recombinant Proteins 
Product Catalog No Vendor 
PE Rat Anti-Mouse IFN 554412 BD Bioscience 
IL2 575402 Biolegend 
IL4 574302 Biolegend 
IL7 577802 Biolegend 
IL12 577002 Biolegend 
LEAF purified Anti-mouse CD3 100313 Biolegend 
LEAF Purified Anti-mouse CD28 102111 Biolegend 
LEAF Purified Anti-mouse IFN 505707 Biolegend 
PE/Cy7 anti-T-bet 644823 Biolegend 
Notch1 (D1E11) XP Rabbit mAb 3608 Cell Signaling Technology 
Cleaved Notch1 (Val1744) (D3B8) 
Rabbit mAb 
4147 Cell Signaling Technology 
RBPSUH 5442 Cell Signaling Technology 
Anti-Human/Mouse Notch1 12-5785-82 eBioscience 
Anti-Human/Mouse Notch1 (Purified) 14-5785-81 eBioscience 
Anti-Vinculin Purified 14-9777-80 eBioscience 
ECL Mouse IgG, HRP-linked whole 
antibody 
NA931-1ml GE LifeSciences 
ECL Rabbit IgG, HRP-linked whole 
antibody 
NA934-1ml GE LifeSciences 
RBPJ Antibody (H-50) SC-28713X Santa Cruz Biotechnology 
Normal Rabbit IgG SC-2027X Santa Cruz Biotechnology 
Monoclonal Anti--tubulin T5168 Sigma 
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Table: 5.3. qPCR Primers 
Gene Primers 
ifng 
5’- ATGAACGCTACACACTGCATC 
3’- CCATCCTTTTGCCAGTTCCTC 
tbx21 
5’- CCAGGAAGTTTCATTTGGGAAGC 
3’- ACGTGTGTGTTAGAAGCACTG 
bactin 
5’- GGCTGTATTCCCCTCCATCG 
3’- CCAGTTGGTAACAATGCCATGT 
mir-29ac stem loop  gctaagaccatcatgcgacttagctaaccg 
mir-29b stem loop  GGTTAGACACAAGCGACACTAACCaacact 
mir-29a 
5’- gTgccgtacTAGCACCATCTG 
3’- gcgacttagctaaccgatttc 
mir-29b 
5’- GGCGCGTAGCACCATTTGAAA 
3’- GCGACACTAACCaacactgat 
mir-29c 
5’- gTgccgtCcTAGCACCATTTG 
3’- gcgacttagctaaccgatttc 
sno202 
5’- GCTGTACTGACTTGATGAAAG 
3’- CATCAGATGGAAAAGGGTTCA 
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5.2. Methods 
5.2.1. T Cell Isolation and Activation 
CD4 T cells were isolated from bulk splenocytes by magnetic separation using anti-CD4 
magnetics particles (BD Pharmingen) according to the manufacturer’s instruction. Cells 
were activated in vitro by plating 1 x 106 cells/ml/well of a 12-well plate pre-coated with 
anti-CD3e and anti-CD28 (Biolegend) and crosslinked with anti-hamster IgG (Sigma). 
Cells were cultured in a 1:1 mixture of RPMI 1640:DMEM supplemented with 10% fetal 
bovine serum, L-Glutamine, Sodium Pyruvate, Penicillin/Streptomycin and β-
mercaptoethanol. The following conditions were used for polarization. Th1: 10ug/ml of 
anti-IL-4 and 1ng/ml of recombinant mouse IL-12. Th2: 10ug/ml of anti-IFN and 
1ng/ml of recombinant mouse IL-4. For inhibitor assays, the CD4 T cells were pretreated 
with 25uM of GSI PF-03084014 (Medchem express) for 30 minutes. For NF-B 
inhibition studies, the DO11.10 T cell hybridoma cell lines were treated with 5uM of 
Bay11-7085 (Sigma). 
5.2.2. Western Blotting 
Cells were lysed in RIPA buffer (150mM NaCl, 1% IGEPAL-CA630, 0.1% SDS, 0.5% 
Sodium deoxycholate, 50mM Tris pH 8.0) with protease and phosphatase inhibitors 
(Bimake). Cytoplasmic and nuclear proteins were extracted according to the 
manufacturer’s instruction (Thermo Scientific) Proteins were resolved on an SDS-PAGE 
and transferred to a nitrocellulose membrane (GE Amersham). Membranes were probed 
with specific primary antibody and then incubated with anti-rabbit/ anti-mouse secondary 
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antibody conjugated with horse radish peroxidase (GE Amersham). Membranes were 
developed using Clarity ECL substrate (BioRad)  
For phosphatase assays, the lysates were prepared in RIPA buffer with protease 
inhibitors. The lysates were incubated with lambda phosphatase (New England Biolabs) 
for 30 minutes according to manufacturer’s instruction. 
5.2.3. Intracellular Staining and FACS analysis 
Activated CD4 T cells were harvested at indicated time points and restimulated with plate 
bound anti-CD3 for 5 hours with BD Golgi Stop (Monensin). Intracellular staining was 
performed to detect Notch-1, T-bet and IFN using FoxP3 staining buffer set 
(eBioscience) following the manufacturer’s instructions. Data were acquired on a BD 
FACS Fortessa and analyzed using FlowJo Software. Intracellular cleaved Notch1 was 
probed with anti-Notch1 antibody (Cell Signaling Technologies) and anti-rabbit 
secondary antibody conjugated with horse radish peroxidase (GE Amersham) 
5.2.4. Real Time PCR 
Activated CD4 T cells were harvested at indicated time points and total RNA was 
extracted using Zymo Quick-RNA Mini Prep kit following the manufacturer’s 
instruction. Total RNA was reverse transcribed with oligo-dT or stem loop primers using 
MuLV Reverse Transcriptase. Stem-Loop primers for miRNA quantification was 
designed as described200. Quantitative Real time PCR was performed using 2x SYBR 
Green Master mix (Bimake). Transcripts were quantified using the 2-CT (Livak) 
method. 
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5.2.5. Chromatin Immunoprecipitation 
Cells were treated with 1% formaldehyde to crosslink proteins to DNA, and treated with 
125mM glycine to quench unreacted formaldehyde and lysed in SDS lysis buffer (1% 
SDS, 10mM EDTA and 50mM Tris pH8.1). Cells were sonicated using Sonicator – 
XL2020 (Misonix Incorporated) (5s ON/15s OFF) for 90 seconds to shear the DNA. 
Sonicated lysates were diluted 10-fold with ChIP dilution buffer (0.01% SDS, 1.1% 
Triton X-100, 1.2mM EDTA, 16.7mM Tris pH 8.1, 167mM NaCl) and precleared with 
Protein A/G PLUS agarose beads (Santa Cruz Biotechnology). Lysates were 
immunoprecipitated with 4ug anti-CSL (Santa Cruz Biotechnology), 1:100 anti-Notch1 
(Cell signaling) or normal rabbit IgG control (Santa Cruz Biotechnology). Protein-DNA 
complex were recovered by adding agarose beads and washed as follows; low-salt buffer 
(0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris pH8.1 and 150mM NaCl), high-
salt buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris pH 8.1), LiCl wash 
buffer (0.25M LiCl, 1% IGEPAL-CA630, 1% Sodium deoxycholate, 1mM EDTA and 
10mM Tris pH8.1) and TE Buffer (1mM EDTA and 10mM Tris, pH8.1). After eluting 
the DNA-protein complex, cross-linking was reversed overnight at 65 C. Following 
Proteinase K digestion, DNA was extracted using DNA extraction kit (Biobasic). CSL-
Notch1 binding region in miR-29 promoter were amplified using specific primers as 
described160. 
5.2.6. Luciferase Assay 
NIH3T3 cell lines were transfected with indicated vectors or with control vectors as 
mentioned in the figure legend using Xtremegene transfection reagent. Luciferase assay 
was performed using Dual-Luciferase Reporter assay system after 48 hours of 
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transfection according to the manufacturer’s instruction. Firefly luciferase activity was 
normalized against Renilla luciferase activity. 
5.2.7. Statistical Analysis 
All data are represented as mean +/- SD. Statistical Analysis was performed using 
GraphPad Prism 7 Software. p values were determined using unpaired t test or 2-way 
ANOVA as mentioned. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
74 
 
BIBLIOGRAPHY 
 
1. Luckheeram, R.V., Zhou, R., Verma, A.D. & Xia, B. CD4(+)T cells: 
differentiation and functions. Clin Dev Immunol 2012, 925135. 
 
2. Afkarian, M. et al. T-bet is a STAT1-induced regulator of IL-12R expression in 
naive CD4+ T cells. Nat Immunol 3, 549-557 (2002). 
 
3. Lugo-Villarino, G., Maldonado-Lopez, R., Possemato, R., Penaranda, C. & 
Glimcher, L.H. T-bet is required for optimal production of IFN-gamma and 
antigen-specific T cell activation by dendritic cells. Proc Natl Acad Sci U S A 
100, 7749-7754 (2003). 
 
4. Oestreich, K.J., Huang, A.C. & Weinmann, A.S. The lineage-defining factors T-
bet and Bcl-6 collaborate to regulate Th1 gene expression patterns. J Exp Med 
208, 1001-1013. 
 
5. Lighvani, A.A. et al. T-bet is rapidly induced by interferon-gamma in lymphoid 
and myeloid cells. Proc Natl Acad Sci U S A 98, 15137-15142 (2001). 
 
6. Nishikomori, R. et al. Activated STAT4 has an essential role in Th1 
differentiation and proliferation that is independent of its role in the maintenance 
of IL-12R beta 2 chain expression and signaling. J Immunol 169, 4388-4398 
(2002). 
 
7. Glimcher, L.H. & Murphy, K.M. Lineage commitment in the immune system: the 
T helper lymphocyte grows up. Genes Dev 14, 1693-1711 (2000). 
 
8. Kaplan, M.H., Schindler, U., Smiley, S.T. & Grusby, M.J. Stat6 is required for 
mediating responses to IL-4 and for development of Th2 cells. Immunity 4, 313-
319 (1996). 
 
9. Zhu, J., Guo, L., Watson, C.J., Hu-Li, J. & Paul, W.E. Stat6 is necessary and 
sufficient for IL-4's role in Th2 differentiation and cell expansion. J Immunol 166, 
7276-7281 (2001). 
 
10. Usui, T., Nishikomori, R., Kitani, A. & Strober, W. GATA-3 suppresses Th1 
development by downregulation of Stat4 and not through effects on IL-12Rbeta2 
chain or T-bet. Immunity 18, 415-428 (2003). 
 
11. Cote-Sierra, J. et al. Interleukin 2 plays a central role in Th2 differentiation. Proc 
Natl Acad Sci U S A 101, 3880-3885 (2004). 
 
12. Kim, J.I., Ho, I.C., Grusby, M.J. & Glimcher, L.H. The transcription factor c-Maf 
controls the production of interleukin-4 but not other Th2 cytokines. Immunity 10, 
745-751 (1999). 
75 
 
13. Zhu, J., Cote-Sierra, J., Guo, L. & Paul, W.E. Stat5 activation plays a critical role 
in Th2 differentiation. Immunity 19, 739-748 (2003). 
 
14. Bettelli, E. et al. Reciprocal developmental pathways for the generation of 
pathogenic effector TH17 and regulatory T cells. Nature 441, 235-238 (2006). 
 
15. Manel, N., Unutmaz, D. & Littman, D.R. The differentiation of human T(H)-17 
cells requires transforming growth factor-beta and induction of the nuclear 
receptor RORgammat. Nat Immunol 9, 641-649 (2008). 
 
16. Mangan, P.R. et al. Transforming growth factor-beta induces development of the 
T(H)17 lineage. Nature 441, 231-234 (2006). 
 
17. Veldhoen, M., Hocking, R.J., Atkins, C.J., Locksley, R.M. & Stockinger, B. 
TGFbeta in the context of an inflammatory cytokine milieu supports de novo 
differentiation of IL-17-producing T cells. Immunity 24, 179-189 (2006). 
 
18. Volpe, E. et al. A critical function for transforming growth factor-beta, interleukin 
23 and proinflammatory cytokines in driving and modulating human T(H)-17 
responses. Nat Immunol 9, 650-657 (2008). 
 
19. Chen, W. et al. Conversion of peripheral CD4+CD25- naive T cells to 
CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor 
Foxp3. J Exp Med 198, 1875-1886 (2003). 
 
20. Schmitt, E.G. & Williams, C.B. Generation and function of induced regulatory T 
cells. Front Immunol 4, 152. 
 
21. Fontenot, J.D., Gavin, M.A. & Rudensky, A.Y. Foxp3 programs the development 
and function of CD4+CD25+ regulatory T cells. Nat Immunol 4, 330-336 (2003). 
 
22. Yagi, H. et al. Crucial role of FOXP3 in the development and function of human 
CD25+CD4+ regulatory T cells. Int Immunol 16, 1643-1656 (2004). 
 
23. Yoshimura, A. & Muto, G. TGF-beta function in immune suppression. Curr Top 
Microbiol Immunol 350, 127-147. 
 
24. Brandenburg, S. et al. IL-2 induces in vivo suppression by 
CD4(+)CD25(+)Foxp3(+) regulatory T cells. Eur J Immunol 38, 1643-1653 
(2008). 
 
25. Burchill, M.A., Yang, J., Vogtenhuber, C., Blazar, B.R. & Farrar, M.A. IL-2 
receptor beta-dependent STAT5 activation is required for the development of 
Foxp3+ regulatory T cells. J Immunol 178, 280-290 (2007). 
76 
 
26. Davidson, T.S., DiPaolo, R.J., Andersson, J. & Shevach, E.M. Cutting Edge: IL-2 
is essential for TGF-beta-mediated induction of Foxp3+ T regulatory cells. J 
Immunol 178, 4022-4026 (2007). 
 
27. Laurence, A. et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell 
generation. Immunity 26, 371-381 (2007). 
 
28. Akiba, H. et al. The role of ICOS in the CXCR5+ follicular B helper T cell 
maintenance in vivo. J Immunol 175, 2340-2348 (2005). 
 
29. Bossaller, L. et al. ICOS deficiency is associated with a severe reduction of 
CXCR5+CD4 germinal center Th cells. J Immunol 177, 4927-4932 (2006). 
 
30. Halonen, S.K., Taylor, G.A. & Weiss, L.M. Gamma interferon-induced inhibition 
of Toxoplasma gondii in astrocytes is mediated by IGTP. Infect Immun 69, 5573-
5576 (2001). 
 
31. Bending, D. et al. Highly purified Th17 cells from BDC2.5NOD mice convert 
into Th1-like cells in NOD/SCID recipient mice. J Clin Invest 119, 565-572 
(2009). 
 
32. Lee, Y.K. et al. Late developmental plasticity in the T helper 17 lineage. 
Immunity 30, 92-107 (2009). 
 
33. Xu, L., Kitani, A., Fuss, I. & Strober, W. Cutting edge: regulatory T cells induce 
CD4+CD25-Foxp3- T cells or are self-induced to become Th17 cells in the 
absence of exogenous TGF-beta. J Immunol 178, 6725-6729 (2007). 
 
34. Zhou, L., Chong, M.M. & Littman, D.R. Plasticity of CD4+ T cell lineage 
differentiation. Immunity 30, 646-655 (2009). 
 
35. Artavanis-Tsakonas, S., Rand, M.D. & Lake, R.J. Notch signaling: cell fate 
control and signal integration in development. Science 284, 770-776 (1999). 
 
36. Mohr, O.L. Character Changes Caused by Mutation of an Entire Region of a 
Chromosome in Drosophila. Genetics 4, 275-282 (1919). 
 
37. Poulson, D.F. Chromosomal Deficiencies and the Embryonic Development of 
Drosophila Melanogaster. Proc Natl Acad Sci U S A 23, 133-137 (1937). 
 
38. Bray, S.J. Notch signalling: a simple pathway becomes complex. Nat Rev Mol 
Cell Biol 7, 678-689 (2006). 
 
39. Gordon, W.R. et al. Mechanical Allostery: Evidence for a Force Requirement in 
the Proteolytic Activation of Notch. Dev Cell 33, 729-736. 
77 
 
40. Weng, A.P. et al. Activating mutations of NOTCH1 in human T cell acute 
lymphoblastic leukemia. Science 306, 269-271 (2004). 
 
41. Yuan, J.S., Kousis, P.C., Suliman, S., Visan, I. & Guidos, C.J. Functions of notch 
signaling in the immune system: consensus and controversies. Annu Rev Immunol 
28, 343-365. 
 
42. Blaumueller, C.M., Qi, H., Zagouras, P. & Artavanis-Tsakonas, S. Intracellular 
cleavage of Notch leads to a heterodimeric receptor on the plasma membrane. 
Cell 90, 281-291 (1997). 
 
43. Logeat, F. et al. The Notch1 receptor is cleaved constitutively by a furin-like 
convertase. Proc Natl Acad Sci U S A 95, 8108-8112 (1998). 
 
44. Kurooka, H., Kuroda, K. & Honjo, T. Roles of the ankyrin repeats and C-terminal 
region of the mouse notch1 intracellular region. Nucleic Acids Res 26, 5448-5455 
(1998). 
 
45. D'Souza, B., Meloty-Kapella, L. & Weinmaster, G. Canonical and non-canonical 
Notch ligands. Curr Top Dev Biol 92, 73-129. 
 
46. Gordon, W.R. et al. Structure of the Notch1-negative regulatory region: 
implications for normal activation and pathogenic signaling in T-ALL. Blood 113, 
4381-4390 (2009). 
 
47. Brou, C. et al. A novel proteolytic cleavage involved in Notch signaling: the role 
of the disintegrin-metalloprotease TACE. Mol Cell 5, 207-216 (2000). 
 
48. De Strooper, B. et al. A presenilin-1-dependent gamma-secretase-like protease 
mediates release of Notch intracellular domain. Nature 398, 518-522 (1999). 
 
49. Struhl, G. & Adachi, A. Nuclear access and action of notch in vivo. Cell 93, 649-
660 (1998). 
 
50. Ye, Y., Lukinova, N. & Fortini, M.E. Neurogenic phenotypes and altered Notch 
processing in Drosophila Presenilin mutants. Nature 398, 525-529 (1999). 
 
51. Fortini, M.E. Gamma-secretase-mediated proteolysis in cell-surface-receptor 
signalling. Nat Rev Mol Cell Biol 3, 673-684 (2002). 
 
52. Mumm, J.S. & Kopan, R. Notch signaling: from the outside in. Dev Biol 228, 
151-165 (2000). 
 
53. Selkoe, D. & Kopan, R. Notch and Presenilin: regulated intramembrane 
proteolysis links development and degeneration. Annu Rev Neurosci 26, 565-597 
(2003). 
78 
 
54. Kageyama, R., Ohtsuka, T. & Kobayashi, T. The Hes gene family: repressors and 
oscillators that orchestrate embryogenesis. Development 134, 1243-1251 (2007). 
 
55. Fryer, C.J., White, J.B. & Jones, K.A. Mastermind recruits CycC:CDK8 to 
phosphorylate the Notch ICD and coordinate activation with turnover. Mol Cell 
16, 509-520 (2004). 
 
56. Hsieh, J.J., Zhou, S., Chen, L., Young, D.B. & Hayward, S.D. CIR, a corepressor 
linking the DNA binding factor CBF1 to the histone deacetylase complex. Proc 
Natl Acad Sci U S A 96, 23-28 (1999). 
 
57. Kao, H.Y. et al. A histone deacetylase corepressor complex regulates the Notch 
signal transduction pathway. Genes Dev 12, 2269-2277 (1998). 
 
58. Oswald, F. et al. RBP-Jkappa/SHARP recruits CtIP/CtBP corepressors to silence 
Notch target genes. Mol Cell Biol 25, 10379-10390 (2005). 
 
59. Maillard, I. et al. Mastermind critically regulates Notch-mediated lymphoid cell 
fate decisions. Blood 104, 1696-1702 (2004). 
 
60. Wang, J. et al. Human Notch-1 inhibits NF-kappa B activity in the nucleus 
through a direct interaction involving a novel domain. J Immunol 167, 289-295 
(2001). 
 
61. Maillard, I., Adler, S.H. & Pear, W.S. Notch and the immune system. Immunity 
19, 781-791 (2003). 
 
62. Fryer, C.J., Lamar, E., Turbachova, I., Kintner, C. & Jones, K.A. Mastermind 
mediates chromatin-specific transcription and turnover of the Notch enhancer 
complex. Genes Dev 16, 1397-1411 (2002). 
 
63. Petcherski, A.G. & Kimble, J. Mastermind is a putative activator for Notch. Curr 
Biol 10, R471-473 (2000). 
 
64. Guruharsha, K.G., Kankel, M.W. & Artavanis-Tsakonas, S. The Notch signalling 
system: recent insights into the complexity of a conserved pathway. Nat Rev 
Genet 13, 654-666. 
 
65. Martinez Arias, A., Zecchini, V. & Brennan, K. CSL-independent Notch 
signalling: a checkpoint in cell fate decisions during development? Curr Opin 
Genet Dev 12, 524-533 (2002). 
 
66. Rusconi, J.C. & Corbin, V. Evidence for a novel Notch pathway required for 
muscle precursor selection in Drosophila. Mech Dev 79, 39-50 (1998). 
 
79 
 
67. Shawber, C. et al. Notch signaling inhibits muscle cell differentiation through a 
CBF1-independent pathway. Development 122, 3765-3773 (1996). 
 
68. Hurlbut, G.D., Kankel, M.W., Lake, R.J. & Artavanis-Tsakonas, S. Crossing 
paths with Notch in the hyper-network. Curr Opin Cell Biol 19, 166-175 (2007). 
 
69. Sanalkumar, R., Dhanesh, S.B. & James, J. Non-canonical activation of Notch 
signaling/target genes in vertebrates. Cell Mol Life Sci 67, 2957-2968. 
 
70. Andersen, P., Uosaki, H., Shenje, L.T. & Kwon, C. Non-canonical Notch 
signaling: emerging role and mechanism. Trends Cell Biol 22, 257-265. 
 
71. Hayward, P., Kalmar, T. & Arias, A.M. Wnt/Notch signalling and information 
processing during development. Development 135, 411-424 (2008). 
 
72. Guan, E. et al. T cell leukemia-associated human Notch/translocation-associated 
Notch homologue has I kappa B-like activity and physically interacts with nuclear 
factor-kappa B proteins in T cells. J Exp Med 183, 2025-2032 (1996). 
 
73. Osipo, C., Golde, T.E., Osborne, B.A. & Miele, L.A. Off the beaten pathway: the 
complex cross talk between Notch and NF-kappaB. Lab Invest 88, 11-17 (2008). 
 
74. Palaga, T., Miele, L., Golde, T.E. & Osborne, B.A. TCR-mediated Notch 
signaling regulates proliferation and IFN-gamma production in peripheral T cells. 
J Immunol 171, 3019-3024 (2003). 
 
75. Shin, H.M. et al. Notch1 augments NF-kappaB activity by facilitating its nuclear 
retention. EMBO J 25, 129-138 (2006). 
 
76. Bachmann, E., Krogh, T.N., Hojrup, P., Skjodt, K. & Teisner, B. Mouse fetal 
antigen 1 (mFA1), the circulating gene product of mdlk, pref-1 and SCP-1: 
isolation, characterization and biology. J Reprod Fertil 107, 279-285 (1996). 
 
77. D'Souza, B., Miyamoto, A. & Weinmaster, G. The many facets of Notch ligands. 
Oncogene 27, 5148-5167 (2008). 
 
78. Laborda, J., Sausville, E.A., Hoffman, T. & Notario, V. dlk, a putative 
mammalian homeotic gene differentially expressed in small cell lung carcinoma 
and neuroendocrine tumor cell line. J Biol Chem 268, 3817-3820 (1993). 
 
79. Smas, C.M. & Sul, H.S. Pref-1, a protein containing EGF-like repeats, inhibits 
adipocyte differentiation. Cell 73, 725-734 (1993). 
 
80. Traustadottir, G.A. et al. Evidence of non-canonical NOTCH signaling: Delta-like 
1 homolog (DLK1) directly interacts with the NOTCH1 receptor in mammals. 
Cell Signal 28, 246-254. 
80 
 
81. Eiraku, M. et al. DNER acts as a neuron-specific Notch ligand during Bergmann 
glial development. Nat Neurosci 8, 873-880 (2005). 
 
82. Krivtsov, A.V. et al. Jedi--a novel transmembrane protein expressed in early 
hematopoietic cells. J Cell Biochem 101, 767-784 (2007). 
 
83. Cui, X.Y. et al. NB-3/Notch1 pathway via Deltex1 promotes neural progenitor 
cell differentiation into oligodendrocytes. J Biol Chem 279, 25858-25865 (2004). 
 
84. Baker, N.E., Mlodzik, M. & Rubin, G.M. Spacing differentiation in the 
developing Drosophila eye: a fibrinogen-related lateral inhibitor encoded by 
scabrous. Science 250, 1370-1377 (1990). 
 
85. Mlodzik, M., Baker, N.E. & Rubin, G.M. Isolation and expression of scabrous, a 
gene regulating neurogenesis in Drosophila. Genes Dev 4, 1848-1861 (1990). 
86. Wesley, C.S. Notch and wingless regulate expression of cuticle patterning genes. 
Mol Cell Biol 19, 5743-5758 (1999). 
 
87. Komatsu, H. et al. OSM-11 facilitates LIN-12 Notch signaling during 
Caenorhabditis elegans vulval development. PLoS Biol 6, e196 (2008). 
 
88. Gibson, M.A. et al. Further characterization of proteins associated with elastic 
fiber microfibrils including the molecular cloning of MAGP-2 (MP25). J Biol 
Chem 271, 1096-1103 (1996). 
 
89. Sakamoto, K. et al. The nephroblastoma overexpressed gene (NOV/ccn3) protein 
associates with Notch1 extracellular domain and inhibits myoblast differentiation 
via Notch signaling pathway. J Biol Chem 277, 29399-29405 (2002). 
 
90. Thibout, H. et al. Characterization of human NOV in biological fluids: an enzyme 
immunoassay for the quantification of human NOV in sera from patients with 
diseases of the adrenal gland and of the nervous system. J Clin Endocrinol Metab 
88, 327-336 (2003). 
 
91. Palmer, W.H. & Deng, W.M. Ligand-Independent Mechanisms of Notch Activity. 
Trends Cell Biol 25, 697-707. 
 
92. Vaccari, T., Lu, H., Kanwar, R., Fortini, M.E. & Bilder, D. Endosomal entry 
regulates Notch receptor activation in Drosophila melanogaster. J Cell Biol 180, 
755-762 (2008). 
 
93. Vaccari, T. et al. Comparative analysis of ESCRT-I, ESCRT-II and ESCRT-III 
function in Drosophila by efficient isolation of ESCRT mutants. J Cell Sci 122, 
2413-2423 (2009). 
 
81 
 
94. Hayashi, Y. et al. A novel non-canonical Notch signaling regulates expression of 
synaptic vesicle proteins in excitatory neurons. Sci Rep 6, 23969. 
 
95. Palermo, R., Checquolo, S., Bellavia, D., Talora, C. & Screpanti, I. The molecular 
basis of notch signaling regulation: a complex simplicity. Curr Mol Med 14, 34-
44. 
 
96. Okajima, T. & Irvine, K.D. Regulation of notch signaling by o-linked fucose. Cell 
111, 893-904 (2002). 
 
97. Okajima, T., Xu, A., Lei, L. & Irvine, K.D. Chaperone activity of protein O-
fucosyltransferase 1 promotes notch receptor folding. Science 307, 1599-1603 
(2005). 
 
98. Sasamura, T. et al. neurotic, a novel maternal neurogenic gene, encodes an O-
fucosyltransferase that is essential for Notch-Delta interactions. Development 130, 
4785-4795 (2003). 
 
99. Shi, S. & Stanley, P. Protein O-fucosyltransferase 1 is an essential component of 
Notch signaling pathways. Proc Natl Acad Sci U S A 100, 5234-5239 (2003). 
 
100. Pourquie, O. The segmentation clock: converting embryonic time into spatial 
pattern. Science 301, 328-330 (2003). 
 
101. Sato, Y., Yasuda, K. & Takahashi, Y. Morphological boundary forms by a novel 
inductive event mediated by Lunatic fringe and Notch during somitic 
segmentation. Development 129, 3633-3644 (2002). 
 
102. Yang, L.T. et al. Fringe glycosyltransferases differentially modulate Notch1 
proteolysis induced by Delta1 and Jagged1. Mol Biol Cell 16, 927-942 (2005). 
 
103. Koch, U. et al. Subversion of the T/B lineage decision in the thymus by lunatic 
fringe-mediated inhibition of Notch-1. Immunity 15, 225-236 (2001). 
 
104. Mukherjee, S. et al. STAT5-induced lunatic fringe during Th2 development alters 
delta-like 4-mediated Th2 cytokine production in respiratory syncytial virus-
exacerbated airway allergic disease. J Immunol 192, 996-1003. 
 
105. Visan, I. et al. Regulation of T lymphopoiesis by Notch1 and Lunatic fringe-
mediated competition for intrathymic niches. Nat Immunol 7, 634-643 (2006). 
 
106. Chastagner, P., Israel, A. & Brou, C. Itch/AIP4 mediates Deltex degradation 
through the formation of K29-linked polyubiquitin chains. EMBO Rep 7, 1147-
1153 (2006). 
 
82 
 
107. Chastagner, P., Israel, A. & Brou, C. AIP4/Itch regulates Notch receptor 
degradation in the absence of ligand. PLoS One 3, e2735 (2008). 
 
108. Fostier, M., Evans, D.A., Artavanis-Tsakonas, S. & Baron, M. Genetic 
characterization of the Drosophila melanogaster Suppressor of deltex gene: A 
regulator of notch signaling. Genetics 150, 1477-1485 (1998). 
 
109. Mazaleyrat, S.L. et al. Down-regulation of Notch target gene expression by 
Suppressor of deltex. Dev Biol 255, 363-372 (2003). 
 
110. Qiu, L. et al. Recognition and ubiquitination of Notch by Itch, a hect-type E3 
ubiquitin ligase. J Biol Chem 275, 35734-35737 (2000). 
 
111. Hori, K., Sen, A., Kirchhausen, T. & Artavanis-Tsakonas, S. Regulation of 
ligand-independent Notch signal through intracellular trafficking. Commun Integr 
Biol 5, 374-376. 
 
112. Hori, K., Sen, A., Kirchhausen, T. & Artavanis-Tsakonas, S. Synergy between the 
ESCRT-III complex and Deltex defines a ligand-independent Notch signal. J Cell 
Biol 195, 1005-1015. 
 
113. Shimizu, K. et al. Binding of Delta1, Jagged1, and Jagged2 to Notch2 rapidly 
induces cleavage, nuclear translocation, and hyperphosphorylation of Notch2. 
Mol Cell Biol 20, 6913-6922 (2000). 
 
114. Fortini, M.E. Notch signaling: the core pathway and its posttranslational 
regulation. Dev Cell 16, 633-647 (2009). 
 
115. Tsunematsu, R. et al. Mouse Fbw7/Sel-10/Cdc4 is required for notch degradation 
during vascular development. J Biol Chem 279, 9417-9423 (2004). 
 
116. Espinosa, L., Ingles-Esteve, J., Aguilera, C. & Bigas, A. Phosphorylation by 
glycogen synthase kinase-3 beta down-regulates Notch activity, a link for Notch 
and Wnt pathways. J Biol Chem 278, 32227-32235 (2003). 
 
117. Foltz, D.R., Santiago, M.C., Berechid, B.E. & Nye, J.S. Glycogen synthase 
kinase-3beta modulates notch signaling and stability. Curr Biol 12, 1006-1011 
(2002). 
 
118. Han, X., Ju, J.H. & Shin, I. Glycogen synthase kinase 3-beta phosphorylates novel 
S/T-P-S/T domains in Notch1 intracellular domain and induces its nuclear 
localization. Biochem Biophys Res Commun 423, 282-288. 
 
119. Jin, Y.H., Kim, H., Oh, M., Ki, H. & Kim, K. Regulation of Notch1/NICD and 
Hes1 expressions by GSK-3alpha/beta. Mol Cells 27, 15-19 (2009). 
83 
 
120. Ishitani, T. et al. Nemo-like kinase suppresses Notch signalling by interfering 
with formation of the Notch active transcriptional complex. Nat Cell Biol 12, 278-
285. 
 
121. Ramakrishnan, G. et al. AKT and 14-3-3 regulate Notch4 nuclear localization. Sci 
Rep 5, 8782. 
 
122. Redmond, L., Oh, S.R., Hicks, C., Weinmaster, G. & Ghosh, A. Nuclear Notch1 
signaling and the regulation of dendritic development. Nat Neurosci 3, 30-40 
(2000). 
 
123. Song, J., Park, S., Kim, M. & Shin, I. Down-regulation of Notch-dependent 
transcription by Akt in vitro. FEBS Lett 582, 1693-1699 (2008). 
 
124. Bigas, A., Martin, D.I. & Milner, L.A. Notch1 and Notch2 inhibit myeloid 
differentiation in response to different cytokines. Mol Cell Biol 18, 2324-2333 
(1998). 
 
125. Milner, L.A. & Bigas, A. Notch as a mediator of cell fate determination in 
hematopoiesis: evidence and speculation. Blood 93, 2431-2448 (1999). 
 
126. Guarani, V. et al. Acetylation-dependent regulation of endothelial Notch 
signalling by the SIRT1 deacetylase. Nature 473, 234-238. 
 
127. Kim, M.Y. et al. Tip60 histone acetyltransferase acts as a negative regulator of 
Notch1 signaling by means of acetylation. Mol Cell Biol 27, 6506-6519 (2007). 
 
128. Han, H. et al. Inducible gene knockout of transcription factor recombination 
signal binding protein-J reveals its essential role in T versus B lineage decision. 
Int Immunol 14, 637-645 (2002). 
 
129. Maillard, I., Fang, T. & Pear, W.S. Regulation of lymphoid development, 
differentiation, and function by the Notch pathway. Annu Rev Immunol 23, 945-
974 (2005). 
 
130. Radtke, F. et al. Deficient T cell fate specification in mice with an induced 
inactivation of Notch1. Immunity 10, 547-558 (1999). 
 
131. Pui, J.C. et al. Notch1 expression in early lymphopoiesis influences B versus T 
lineage determination. Immunity 11, 299-308 (1999). 
 
132. Sade, H., Krishna, S. & Sarin, A. The anti-apoptotic effect of Notch-1 requires 
p56lck-dependent, Akt/PKB-mediated signaling in T cells. J Biol Chem 279, 
2937-2944 (2004). 
 
84 
 
133. Benson, R.A. et al. Notch1 co-localizes with CD4 on activated T cells and Notch 
signaling is required for IL-10 production. Eur J Immunol 35, 859-869 (2005). 
 
134. Laky, K., Evans, S., Perez-Diez, A. & Fowlkes, B.J. Notch signaling regulates 
antigen sensitivity of naive CD4+ T cells by tuning co-stimulation. Immunity 42, 
80-94. 
 
135. Helbig, C. et al. Notch controls the magnitude of T helper cell responses by 
promoting cellular longevity. Proc Natl Acad Sci U S A 109, 9041-9046. 
 
136. Amsen, D., Helbig, C. & Backer, R.A. Notch in T Cell Differentiation: All Things 
Considered. Trends Immunol 36, 802-814. 
 
137. Amsen, D. et al. Instruction of distinct CD4 T helper cell fates by different notch 
ligands on antigen-presenting cells. Cell 117, 515-526 (2004). 
 
138. Maekawa, Y. et al. Delta1-Notch3 interactions bias the functional differentiation 
of activated CD4+ T cells. Immunity 19, 549-559 (2003). 
 
139. Eagar, T.N. et al. Notch 1 signaling regulates peripheral T cell activation. 
Immunity 20, 407-415 (2004). 
 
140. Minter, L.M. et al. Inhibitors of gamma-secretase block in vivo and in vitro T 
helper type 1 polarization by preventing Notch upregulation of Tbx21. Nat 
Immunol 6, 680-688 (2005). 
 
141. Amsen, D. et al. Direct regulation of Gata3 expression determines the T helper 
differentiation potential of Notch. Immunity 27, 89-99 (2007). 
 
142. Bailis, W. et al. Notch simultaneously orchestrates multiple helper T cell 
programs independently of cytokine signals. Immunity 39, 148-159. 
 
143. Auderset, F. et al. Redundant Notch1 and Notch2 signaling is necessary for 
IFNgamma secretion by T helper 1 cells during infection with Leishmania major. 
PLoS Pathog 8, e1002560. 
 
144. Kared, H. et al. Jagged2-expressing hematopoietic progenitors promote regulatory 
T cell expansion in the periphery through notch signaling. Immunity 25, 823-834 
(2006). 
 
145. Keerthivasan, S. et al. Notch signaling regulates mouse and human Th17 
differentiation. J Immunol 187, 692-701. 
 
146. Mukherjee, S., Schaller, M.A., Neupane, R., Kunkel, S.L. & Lukacs, N.W. 
Regulation of T cell activation by Notch ligand, DLL4, promotes IL-17 
production and Rorc activation. J Immunol 182, 7381-7388 (2009). 
85 
 
147. Samon, J.B. et al. Notch1 and TGFbeta1 cooperatively regulate Foxp3 expression 
and the maintenance of peripheral regulatory T cells. Blood 112, 1813-1821 
(2008). 
 
148. Charbonnier, L.M., Wang, S., Georgiev, P., Sefik, E. & Chatila, T.A. Control of 
peripheral tolerance by regulatory T cell-intrinsic Notch signaling. Nat Immunol 
16, 1162-1173. 
 
149. Auderset, F. et al. Notch signaling regulates follicular helper T cell 
differentiation. J Immunol 191, 2344-2350. 
 
150. Ong, C.T., Sedy, J.R., Murphy, K.M. & Kopan, R. Notch and presenilin regulate 
cellular expansion and cytokine secretion but cannot instruct Th1/Th2 fate 
acquisition. PLoS One 3, e2823 (2008). 
 
151. Jacquier, A. The complex eukaryotic transcriptome: unexpected pervasive 
transcription and novel small RNAs. Nat Rev Genet 10, 833-844 (2009). 
 
152. Pagani, M. et al. Role of microRNAs and long-non-coding RNAs in CD4(+) T-
cell differentiation. Immunol Rev 253, 82-96. 
 
153. Bartel, D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 
116, 281-297 (2004). 
 
154. Jeker, L.T. & Bluestone, J.A. MicroRNA regulation of T-cell differentiation and 
function. Immunol Rev 253, 65-81. 
 
155. Baumjohann, D. & Ansel, K.M. MicroRNA-mediated regulation of T helper cell 
differentiation and plasticity. Nat Rev Immunol 13, 666-678. 
 
156. Liu, J., Wu, C.P., Lu, B.F. & Jiang, J.T. Mechanism of T cell regulation by 
microRNAs. Cancer Biol Med 10, 131-137. 
 
157. Li, Q.J. et al. miR-181a is an intrinsic modulator of T cell sensitivity and 
selection. Cell 129, 147-161 (2007). 
 
158. Chong, M.M., Rasmussen, J.P., Rudensky, A.Y. & Littman, D.R. The RNAseIII 
enzyme Drosha is critical in T cells for preventing lethal inflammatory disease. J 
Exp Med 205, 2005-2017 (2008). 
 
159. Cobb, B.S. et al. A role for Dicer in immune regulation. J Exp Med 203, 2519-
2527 (2006). 
 
160. Ma, F. et al. The microRNA miR-29 controls innate and adaptive immune 
responses to intracellular bacterial infection by targeting interferon-gamma. Nat 
Immunol 12, 861-869. 
86 
 
161. Muljo, S.A. et al. Aberrant T cell differentiation in the absence of Dicer. J Exp 
Med 202, 261-269 (2005). 
 
162. Steiner, D.F. et al. MicroRNA-29 regulates T-box transcription factors and 
interferon-gamma production in helper T cells. Immunity 35, 169-181. 
 
163. O'Donnell, K.A., Wentzel, E.A., Zeller, K.I., Dang, C.V. & Mendell, J.T. c-Myc-
regulated microRNAs modulate E2F1 expression. Nature 435, 839-843 (2005). 
 
164. Bronevetsky, Y. et al. T cell activation induces proteasomal degradation of 
Argonaute and rapid remodeling of the microRNA repertoire. J Exp Med 210, 
417-432. 
 
165. Li, Z., Wu, F., Brant, S.R. & Kwon, J.H. IL-23 receptor regulation by Let-7f in 
human CD4+ memory T cells. J Immunol 186, 6182-6190. 
 
166. Lu, T.X. et al. MicroRNA-21 limits in vivo immune response-mediated activation 
of the IL-12/IFN-gamma pathway, Th1 polarization, and the severity of delayed-
type hypersensitivity. J Immunol 187, 3362-3373. 
 
167. Rossi, R.L. et al. Distinct microRNA signatures in human lymphocyte subsets and 
enforcement of the naive state in CD4+ T cells by the microRNA miR-125b. Nat 
Immunol 12, 796-803. 
 
168. Smith, K.M. et al. miR-29ab1 deficiency identifies a negative feedback loop 
controlling Th1 bias that is dysregulated in multiple sclerosis. J Immunol 189, 
1567-1576. 
 
169. Mott, J.L. et al. Transcriptional suppression of mir-29b-1/mir-29a promoter by c-
Myc, hedgehog, and NF-kappaB. J Cell Biochem 110, 1155-1164. 
 
170. Wang, H. et al. NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal 
myogenesis and rhabdomyosarcoma. Cancer Cell 14, 369-381 (2008). 
 
171. Andersson, E.R., Sandberg, R. & Lendahl, U. Notch signaling: simplicity in 
design, versatility in function. Development 138, 3593-3612. 
 
172. van Tetering, G. et al. Metalloprotease ADAM10 is required for Notch1 site 2 
cleavage. J Biol Chem 284, 31018-31027 (2009). 
 
173. van Tetering, G. & Vooijs, M. Proteolytic cleavage of Notch: "HIT and RUN". 
Curr Mol Med 11, 255-269. 
 
174. Bozkulak, E.C. & Weinmaster, G. Selective use of ADAM10 and ADAM17 in 
activation of Notch1 signaling. Mol Cell Biol 29, 5679-5695 (2009). 
87 
 
175. Ray, W.J. et al. Evidence for a physical interaction between presenilin and Notch. 
Proc Natl Acad Sci U S A 96, 3263-3268 (1999). 
 
176. Yamamoto, S., Charng, W.L. & Bellen, H.J. Endocytosis and intracellular 
trafficking of Notch and its ligands. Curr Top Dev Biol 92, 165-200. 
 
177. Wilkin, M. et al. Drosophila HOPS and AP-3 complex genes are required for a 
Deltex-regulated activation of notch in the endosomal trafficking pathway. Dev 
Cell 15, 762-772 (2008). 
 
178. Wilkin, M.B. et al. Regulation of notch endosomal sorting and signaling by 
Drosophila Nedd4 family proteins. Curr Biol 14, 2237-2244 (2004). 
 
179. Minter, L.M. & Osborne, B.A. Canonical and non-canonical Notch signaling in 
CD4(+) T cells. Curr Top Microbiol Immunol 360, 99-114. 
 
180. Osborne, B.A. & Minter, L.M. Notch signalling during peripheral T-cell 
activation and differentiation. Nat Rev Immunol 7, 64-75 (2007). 
 
181. Bailis, W., Yashiro-Ohtani, Y. & Pear, W.S. Identifying direct Notch 
transcriptional targets using the GSI-washout assay. Methods Mol Biol 1187, 247-
254. 
 
182. Pollard, K.M., Cauvi, D.M., Toomey, C.B., Morris, K.V. & Kono, D.H. 
Interferon-gamma and systemic autoimmunity. Discov Med 16, 123-131. 
 
183. Kriegel, A.J., Liu, Y., Fang, Y., Ding, X. & Liang, M. The miR-29 family: 
genomics, cell biology, and relevance to renal and cardiovascular injury. Physiol 
Genomics 44, 237-244. 
 
184. Dongre, A. et al. Non-Canonical Notch Signaling Drives Activation and 
Differentiation of Peripheral CD4(+) T Cells. Front Immunol 5, 54. 
 
185. Papayannidis, C. et al. A Phase 1 study of the novel gamma-secretase inhibitor 
PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell 
lymphoblastic lymphoma. Blood Cancer J 5, e350. 
 
186. Contreras-Cornejo, H. et al. The CSL proteins, versatile transcription factors and 
context dependent corepressors of the notch signaling pathway. Cell Div 11, 12. 
 
187. Roderick, J.E. et al. Therapeutic targeting of NOTCH signaling ameliorates 
immune-mediated bone marrow failure of aplastic anemia. J Exp Med 210, 1311-
1329. 
 
88 
 
188. Bazzini, A.A., Lee, M.T. & Giraldez, A.J. Ribosome profiling shows that miR-
430 reduces translation before causing mRNA decay in zebrafish. Science 336, 
233-237. 
 
189. Krishnamoorthy, V. et al. Repression of Ccr9 transcription in mouse T 
lymphocyte progenitors by the Notch signaling pathway. J Immunol 194, 3191-
3200. 
 
190. Fasnacht, N. et al. Specific fibroblastic niches in secondary lymphoid organs 
orchestrate distinct Notch-regulated immune responses. J Exp Med 211, 2265-
2279. 
 
191. Mustelin, T. & Tasken, K. Positive and negative regulation of T-cell activation 
through kinases and phosphatases. Biochem J 371, 15-27 (2003). 
 
192. Stanford, S.M., Rapini, N. & Bottini, N. Regulation of TCR signalling by tyrosine 
phosphatases: from immune homeostasis to autoimmunity. Immunology 137, 1-
19. 
 
193. Finlay, D. & Cantrell, D. The coordination of T-cell function by serine/threonine 
kinases. Cold Spring Harb Perspect Biol 3, a002261. 
 
194. Owens, D.M. & Keyse, S.M. Differential regulation of MAP kinase signalling by 
dual-specificity protein phosphatases. Oncogene 26, 3203-3213 (2007). 
 
195. Zhang, Y. et al. MKP-1 is necessary for T cell activation and function. J Biol 
Chem 284, 30815-30824 (2009). 
 
196. Jo, H.S., Kang, K.H., Joe, C.O. & Kim, J.W. Pten coordinates retinal 
neurogenesis by regulating Notch signalling. EMBO J 31, 817-828. 
 
197. Jeffries, S., Robbins, D.J. & Capobianco, A.J. Characterization of a high-
molecular-weight Notch complex in the nucleus of Notch(ic)-transformed RKE 
cells and in a human T-cell leukemia cell line. Mol Cell Biol 22, 3927-3941 
(2002). 
 
198. Jeffries, S. & Capobianco, A.J. Neoplastic transformation by Notch requires 
nuclear localization. Mol Cell Biol 20, 3928-3941 (2000). 
 
199. Yun, J. et al. p53 Modulates Notch Signaling in MCF-7 Breast Cancer Cells by 
Associating With the Notch Transcriptional Complex Via MAML1. J Cell 
Physiol 230, 3115-3127. 
 
200. Kramer, M.F. Stem-loop RT-qPCR for miRNAs. Curr Protoc Mol Biol Chapter 
15, Unit 15 10. 
 
